Q/C Technologies Q3 loss narrows to $942K
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Q/C Technologies, Inc. (QCLS) reported no product revenue in the quarter ended September 30, 2026 and a net loss of $941,793, versus $2,811,388 in the same 2025 quarter. The smaller quarterly loss coincided with a $1,541,000 fair-value gain on derivative liabilities; the 2025 quarter recorded a $1,059,000 loss on that measure.
For the first nine months, net loss was $11,313,780 versus $5,732,326 in 2025, and operating cash used was $6,640,396 versus $5,865,877. Stock-based compensation expense was $5,343,060, compared with $189,490. As of September 30, 2026, cash was $2,585,051 and marketable securities were $6,805,270. Management said available resources were sufficient for the current operating budget and contractual obligations due over the next 12 months from issuance.
QCLS terminated its LightSolver technology license effective June 26, 2026; its subsidiary LPU was relieved of additional milestone-payment obligations, and LightSolver has no further contingent-consideration rights. The company recorded a $3,177,999 impairment charge for the license and said it is now focused on an optical processing unit for AI inference, while researching quantum/laser-based computer technology.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointThird-quarter net loss narrowed to $941,793 from $2,811,388 a year earlier.
Negative
- Major pointNine-month net loss widened to $11,313,780 from $5,732,326.
- Moderate pointNine-month operating cash used increased to $6,640,396 from $5,865,877.
Filing Explained
Common shares outstanding rose from 7,690,403 at December 31, 2025, to 8,499,379 at September 30, and 8,619,201 by November 13, 2026.
This quarterly report records
Separately, the filing lists 14,950,873 potential common shares from warrants, options, restricted stock units and convertible preferred stock, excluded from diluted loss per share because they would be anti-dilutive; this is potential issuance, not a statement that all those shares have been issued.
If those instruments are exercised or converted into additional common shares, the share count would rise further and existing holders’ percentage ownership would fall absent offsetting changes.
Key Figures
Key Terms
Level 3 financial
bifurcated embedded derivative financial
anti-dilutive financial
right-of-use assets financial
optical processing unit technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was QCLS’s net loss in the third quarter and first nine months of 2026?
How much cash and marketable securities did QCLS report at September 30, 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For
the quarterly period ended
or
For the transition period from ____________ to ____________
Commission
File Number:
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification Number) | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Former name, former address and former fiscal year, if changed since last report: N/A
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class: | Trading Symbol(s) | Name of Each Exchange on Which Registered: | ||
| The
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of November 13, 2026, the registrant had
TABLE OF CONTENTS
| PART I – FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements | 3 |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 38 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 53 |
| Item 4. | Controls and Procedures | 53 |
| PART II – OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 54 |
| Item 1A. | Risk Factors | 54 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 54 |
| Item 3. | Defaults Upon Senior Securities | 54 |
| Item 4. | Mine Safety Disclosures | 54 |
| Item 5. | Other Information | 54 |
| Item 6. | Exhibits | 55 |
| Signatures | 56 | |
| 2 |
PART I - Financial Information
Item 1. Financial Statements.
Q/C TECHNOLOGIES, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
September 30, 2026 and December 31, 2025
(unaudited) September 30, 2026 |
December 31, 2025 | |||||||
| As of | ||||||||
(unaudited) September 30, 2026 |
December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $ | $ | ||||||
| Marketable Securities | ||||||||
| Other Receivables | ||||||||
| Prepaid Expenses | ||||||||
| Total Current Assets | ||||||||
| Non-Current Assets | ||||||||
| Property, Plant and Equipment, net | - | |||||||
| Operating Lease Right-of-Use Asset, net | - | |||||||
| Technology License | - | |||||||
| Goodwill | ||||||||
| Other Assets | - | |||||||
| Total Non-Current Assets | ||||||||
| Total Assets | $ | $ | ||||||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Trade and Other Payables | $ | $ | ||||||
| Due to MyMD FL Shareholders | ||||||||
| Operating Lease Liability | - | |||||||
| Dividends Payable | ||||||||
| License Fees Payable | ||||||||
| Derivative Liability | ||||||||
| Total Current Liabilities | ||||||||
| Non-Current Liabilities | ||||||||
| Contingent Consideration Payable, net of current | - | |||||||
| Operating Lease Liability, net of current | - | |||||||
| Total Non-Current Liabilities | ||||||||
| Total Liabilities | ||||||||
| Commitments and Contingencies | - | |||||||
| Mezzanine Equity | ||||||||
| Series G Convertible Preferred Stock, |
||||||||
| Series G Convertible Preferred Stock – Discount | ( |
) | ( |
) | ||||
| Series H Convertible Preferred Stock, |
||||||||
| Convertible Preferred Stock, value | ||||||||
| Series H Convertible Preferred Stock – Discount | ( |
) | ( |
) | ||||
| Convertible Preferred Stock – Discount | ( |
) | ( |
) | ||||
| Series H Convertible Preferred Stock – Derivative | ( |
) | ( |
) | ||||
| Total Mezzanine Equity | ||||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Preferred Stock, par value $ |
||||||||
| Series D Convertible Preferred Stock, $ |
||||||||
| Preferred Stock, value | ||||||||
| Common Stock, par value $ |
||||||||
| Additional Paid in Capital | ||||||||
| Accumulated Deficit | ( |
) | ( |
) | ||||
| Total Stockholders’ Equity | ||||||||
| Total Liabilities and Stockholders’ Equity | $ | $ | ||||||
See accompanying notes to these unaudited condensed consolidated financial statements.
| 3 |
Q/C TECHNOLOGIES, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(unaudited)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Product Revenue | $ | - | $ | - | $ | - | $ | - | ||||||||
| Product Cost of Sales | - | - | - | - | ||||||||||||
| Gross Profit | - | - | - | - | ||||||||||||
| General and Administrative Expenses | ||||||||||||||||
| Research and Development Expenses | ||||||||||||||||
| Stock Based Compensation Expenses | - | |||||||||||||||
| Franchise Tax Expense | ||||||||||||||||
| Series H Warrant Issuance Expenses | - | - | ||||||||||||||
| Transaction Costs Associated with Due Diligence | - | - | ||||||||||||||
| Impairment of Technology License | - | - | - | |||||||||||||
| Loss from Operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other (Income) Expenses | ||||||||||||||||
| Interest and Dividend Income | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Gain on Sale of Investments | ( | ) | - | ( | ) | ( | ) | |||||||||
| Change in fair value of Marketable Securities | ( | ) | ( | ) | ||||||||||||
| Change in fair value of Derivatives Liabilities | ( | ) | ( | ) | ( | ) | ||||||||||
| Total Other (Income)/Expense | ( | ) | ( | ) | ( | ) | ||||||||||
| Loss Before Income Tax | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income Tax Benefit/(Provision) | - | - | - | - | ||||||||||||
| Net Loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Preferred Stock Dividends & Adjustments | ||||||||||||||||
| Net Loss Attributable to Common Stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic and diluted net loss per common share | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average basic and diluted common stock outstanding | ||||||||||||||||
See accompanying notes to these unaudited condensed consolidated financial statements.
| 4 |
Q/C TECHNOLOGIES, INC. AND SUBSIDIARIES
Condensed Consolidated Statement of Changes in Mezzanine Equity and Stockholders’ Equity
For the Three and Nine Months Ended September 30, 2026 and 2025
(unaudited)
| Shares | Series F | Shares | Series F-1 | Shares | Series G | Shares | Series H | Shares | Series D | Shares | Par
Value $0.001 |
Paid
In Capital |
Accumulated Deficit |
Total
Equity |
||||||||||||||||||||||||||||||||||||||||||||||||
| Series F | Series F-1 | Series G | Series H | Series D | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Convertible | Convertible | Convertible | Convertible | Convertible | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock | Preferred Stock | Preferred Stock | Preferred Stock | Preferred Stock | Common Stock | Additional | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Series F | Shares | Series F-1 | Shares | Series G | Shares | Series H | Shares | Series D | Shares | Par
Value $0.001 |
Paid
In Capital |
Accumulated Deficit |
Total
Equity |
||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2025 | - | $ | - | - | $ | - | $ | $ | - | - | $ | $ | $ | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||||
| Adjustment | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||
| Common Stock Warrant Exercises | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based Compensation - Restricted Stock Units | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based Compensation - Stock Options | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based Compensation - Warrants |
- |
- |
- | - |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||
| Stock based compensation - Restricted Stock Awards | - |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | - | $ | - | - | $ | - | $ |
$ | - | - | $ | $ | $ | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock Dividends and Dividend Adjustments | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Common Stock Warrant Issuances and Exercises | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based Compensation - Restricted Stock Units | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based Compensation - Stock Options | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based Compensation - Warrants | - |
- |
- |
- | - |
- |
- |
- |
- |
- |
- |
- |
- | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock based compensation - Restricted Stock Awards | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2026 | - | $ | - | - | $ | - | $ | $ | - | - | $ | $ | $ | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - | ( |
) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based Compensation - Restricted Stock Units | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based Compensation - Stock Options | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based Compensation - Warrants | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock based compensation - Restricted Stock Awards | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | - | $ | - | - | $ | - | $ | $ | - | - | $ | $ | $ | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||||||||||||
| 5 |
| Shares | Series F | Shares | Series F-1 | Shares | Series G | Shares | Series H | Shares | Series I | Shares | Series D | Shares | Par Value $0.001 | Paid In Capital | Accumulated Deficit | Total Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series F Convertible | Series F-1 Convertible | Series G Convertible | Series H Convertible | Series I Convertible | Series D Convertible | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock | Preferred Stock | Preferred Stock | Preferred Stock | Preferred Stock | Preferred Stock | Common Stock | Additional | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Series F | Shares | Series F-1 | Shares | Series G | Shares | Series H | Shares | Series I | Shares | Series D | Shares | Par Value $0.001 | Paid In Capital | Accumulated Deficit | Total Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | - | $ | - | - | $ | - | - | $ | - | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Accelerated Conversion of | ( | ) | ( | ) | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accelerated Conversion of | - | - | ( | ) | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of | - | - | - | - | ( | ) | - | - | - | - | - | - | - | ( | ) | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series G Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock based compensation - stock options | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | - | $ | - | $ | - | - | $ | - | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accelerated Conversion of | ( | ) | ( | ) | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accelerated Conversion of | - | - | ( | ) | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of | - | - | - | - | ( | ) | - | - | - | - | - | - | - | ( | ) | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series G Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| True-up in conjunction with 01 Jun 25 modifications | - | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Shareholder request to reclassify a Series F share conversion to Series F-1 | - | ( | ) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciling adjustments to outstanding shares | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock based compensation - stock options | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | - | $ | - | $ | - | - | $ | - | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Accelerated Conversion of | ( | ) | ( | ) | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accelerated Conversion of Series F Convertible Preferred Stock | (4,382 | ) | (5,130,667 | ) | - | - | - | - | - | - | - | - | 1,321,156 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accelerated Conversion of | - | - | ( | ) | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accelerated Conversion of Series F-1 Convertible Preferred Stock | - | - | (2,065 | ) | - | - | - | - | - | - | - | 399,945 | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of | - | - | - | - | ( | ) | - | - | - | - | - | - | - | ( | ) | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of Series G Convertible Preferred Stock | - | - | - | - | (606 | ) | - | - | - | - | - | - | - | 161,959 | ( | ) | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series G Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of | - | - | - | - | - | - | 7,000 | 2,433,917 | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series H Convertible Preferred Stock, net of discount and offering costs | - | - | - | - | 7,000 | 2,433,917 | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of | - | - | - | - | - | - | - | - | 747,362 | 2,697,977 | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series I Convertible Preferred Stock | - | - | - | - | - | - | 747,3632 | 2,697,977 | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Proceeds from the exercise of common stock warrants | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deemed dividends on final settlement of the Series F Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Deemed dividends on final settlement of the Series F-1 Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Deemed dividends on final settlement of the Series F Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | - | $ | - | - | $ | - | $ | $ | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||
See accompanying notes to these unaudited condensed consolidated financial statements
| 6 |
Q/C TECHNOLOGIES, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(unaudited)
| 2026 | 2025 | |||||||
| For the Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Accrued interest/dividends | - | - | ||||||
| (Gain)/Loss on sale of securities | ( | ) | ( | ) | ||||
| Loss on fair market value of equity investments | ||||||||
| Gain on fair market value of derivatives | ( | ) | ( | ) | ||||
| Amortization of ROU asset | - | |||||||
| Depreciation of fixed assets | - | |||||||
| Impairment of technology license | - | |||||||
| Share-based compensation: | ||||||||
| To directors – options | ||||||||
| To key employees – options | - | |||||||
| To key employees – restricted stock units/awards (RSUs/RSAs) | - | |||||||
| To directors – RSUs/RSAs | - | |||||||
| To non-employees – options | ||||||||
| To non-employees – warrants | - | |||||||
| To non-employees – RSUs/RSAs | - | |||||||
| Change in assets and liabilities: | ||||||||
| Prepaid expenses | ( | ) | ( | ) | ||||
| Security deposits | ( | ) | - | |||||
| Trade and other receivables | - | |||||||
| Trade and other payables | ( | ) | ||||||
| Operating lease liabilities | ( | ) | - | |||||
| License Fees Payable | ( | ) | - | |||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchase of capital equipment | ( | ) | - | |||||
| Purchase of technology license | - | ( | ) | |||||
| Purchases of marketable securities | ( | ) | ( | ) | ||||
| Proceeds from sale of marketable securities | ||||||||
| Net cash provided by investing activities | ||||||||
| Cash flows from financing activities | ||||||||
| Dividends on Preferred Stock | ( | ) | - | |||||
| Net proceeds from the issuance of Series H Convertible Preferred Stock | - | |||||||
| Net proceeds from the exercise of warrants for common stock | ||||||||
| Net cash provided by financing activities | ||||||||
| Net increase/(decrease) in cash and cash equivalents | ||||||||
| Cash at beginning of period | ||||||||
| Cash at end of period | $ | $ | ||||||
| Supplemental cash flow information | ||||||||
| Cash paid for: | ||||||||
| Interest | $ | - | $ | - | ||||
| Income Taxes | $ | - | $ | - | ||||
| Supplemental Schedule of Non-Cash Financing and Investing Activities | ||||||||
| Fair value of Series G Convertible Preferred Stock issued in-lieu of dividends | $ | $ | ||||||
| Initial fair value of derivative liabilities pursuant to the issuance of Series H Convertible Preferred Stock and Warrants | $ | - | $ | |||||
| Contingent Consideration Payable for technology license | $ | - | $ | |||||
| Issuance of Series I Convertible Preferred Stock for technology license | $ | - | $ | |||||
| Accrued dividends on Series G and Series H Convertible Preferred Stock | $ | $ | - | |||||
| Operating lease right of use asset obtained in exchange for lease liability | $ | $ | - | |||||
See accompanying notes to these unaudited condensed consolidated financial statements.
| 7 |
Q/C TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements
Note 1 – Organization and Description of Business
Q/C
Technologies, Inc, formerly known as TNF Pharmaceuticals, Inc., is a Delaware corporation (“QCLS” or the “Company”)
that was incorporated in New Jersey prior to the Reincorporation (as defined below) and was originally incorporated in Florida in November
2014. On July 22, 2024, the Company changed its name from MyMD Pharmaceuticals, Inc. to TNF Pharmaceuticals, Inc. by filing a certificate
of amendment to its certificate of incorporation with the Secretary of State of Delaware. In addition, effective before the open of market
trading on July 24, 2024, the Company’s common stock, par value $
As
part of the transition in the Company’s business model, on September 2, 2025, the Company entered into a Membership Interest Purchase
Agreement (the “MIPA”), by and among the Company, LPU Holdings LLC (“LPU”) and the members of LPU (the “Sellers”),
pursuant to which the Company agreed to acquire
Additionally, these consolidated financial statements include three wholly owned subsidiaries as of September 30, 2026, Akers Acquisition Sub, Inc., Bout Time Marketing Corporation and LPU (together, the “Company”). All material intercompany transactions have been eliminated in consolidation.
The Company has historically been engaged in the development and commercialization of two therapeutic platforms based on well-defined targets: (i) Isomyosamine (formerly known as MYMD-1), an oral, next-generation TNF-α inhibitor with the potential to transform the way TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier. Its ease of oral dosing is a significant differentiator compared to currently available TNF-α inhibitors, all of which require delivery by injection or infusion, and (ii) Supera-CBD.
In 2025, the Company shifted its business strategy to focus on energy-efficient blockchain, cryptocurrency infrastructure, and high-performance computing through quantum-class laser-based computing. The Company’s core strategy had leveraged an exclusive global licensing agreement with LightSolver Ltd. (“LightSolver”) to deploy innovative LPUs, specifically the Company-branded qc-LPU100™, which harnesses the natural properties of light with the goal of achieving high computational speed and energy efficiency. On June 26, 2026, the Company provided notice of its intention to terminate the License Agreement (as defined below), effective as of June 26, 2026 (the “Termination”). In connection with the Termination, the Company was automatically and immediately relieved from its obligation to make any additional milestone payments to LightSolver, and LightSolver has no right to receive any further contingent consideration thereunder. Following the Termination, the Company determined to fully focus its efforts on its optical processing unit initiative, a proprietary silicon photonic computing architecture for artificial intelligence inference. Additionally, the Company is researching and designing quantum/laser-based computer technology.
The Company is pre-revenue and only has investment income for the periods ending 2026 and 2025.
| 8 |
Note 2 – Significant Accounting Policies
(a) Basis of Presentation
The condensed consolidated financial statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
The accompanying unaudited condensed financial statements have been prepared by the Company. These statements include all adjustments (consisting only of normal recurring adjustments) which management believes necessary for a fair presentation of the statements and have been prepared on a consistent basis using the accounting policies described in Note 2 Significant Accounting Policies included in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on April 15, 2026 (the “2025 Annual Report”). Certain financial information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the accompanying disclosures are adequate to make the information presented not misleading. The Notes to Financial Statements including the 2025 Annual Report should be read in conjunction with the accompanying interim financial statements. The interim operating results for the three and nine months ended September 30, 2026, may not be necessarily indicative of the operating results expected for the full year or any future period.
(b) Use of Estimates and Judgments
The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for recording the fair value of financial instruments, derivative financial instruments valuations, research and development expenses, impairment of intangible assets and the valuation of share-based payments.
(c) Correction of Immaterial Errors in Previously Reported Interim Financial Information
In connection with the preparation of the unaudited condensed consolidated financial statements for the quarter ended September 30, 2026, the Company identified errors in the accounting for certain stock-based compensation awards. The errors resulted in the understatement of stock-based compensation expense, additional paid-in capital, and accumulated deficit in the Company’s previously issued Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, and June 30, 2026.
The Company evaluated the error in accordance with SEC Staff Accounting Bulletin No. 99, Materiality, and concluded that the error was not material to any previously issued financial statements. Accordingly, the Company has revised the previously reported interim financial information presented herein.
The revision did not affect the Company’s cash and cash equivalents, total assets, total liabilities, revenues, or cash flows from operating, investing or financing activities for any period presented.
(d) Functional and Presentation Currency
These condensed consolidated financial statements are presented in U.S. Dollars, which is the Company’s functional currency. All financial information has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from cash balances denominated in Foreign Currencies, are recorded in the Condensed Consolidated Statements of Operations.
(e) Comprehensive Income (Loss)
The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220 in reporting comprehensive income. Comprehensive income (loss) is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income (loss). Since the Company has no items of other comprehensive income (loss), comprehensive loss is equal to net loss.
(f) Cash and Cash Equivalents
The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit) that are not restricted as to withdrawal date or use, to be cash equivalents.
| 9 |
(g) Fair Value of Financial Instruments
Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three and nine months ended September 30, 2026. The carrying amounts of cash equivalents, accounts receivable, other current assets, other assets, accounts payable, and accrued expenses approximated their fair values as of September 30, 2026, due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible preferred stock was estimated using a Monte Carlo simulation model, which uses as inputs the fair value of the Company’s Common Stock and estimates for the equity volatility and traded volume volatility of the Company’s Common Stock, the time to maturity of the convertible preferred stock, the risk-free interest rate for a period that approximates the time to maturity, dividend rate, a penalty dividend rate, and the probability of default. The fair value of the warrant liabilities was estimated using the Black Scholes Model which uses as inputs the following weighted average assumptions: dividend yield, expected term in years, equity volatility, and risk-free interest rate.
Fair Value Measurement
The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:
| Level 1 | Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company can access. | ||
| Level 2 | Inputs to the valuation methodology include: | ||
| ● | quoted prices for similar assets or liabilities in active markets; | ||
| ● | quoted prices for identical or similar assets or liabilities in inactive markets; | ||
| ● | inputs other than quoted prices that are observable for the asset or liability; | ||
| ● | inputs that are derived principally from or corroborated by observable market data by correlation or other means | ||
| If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. | |||
| Level 3 | Inputs to the valuation methodology are unobservable and significant to the fair value measurement. | ||
The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.
The following is a description of the valuation methodologies used for assets measured at fair value as of September 30, 2026 and December 31, 2025.
Schedule of Marketable Securities
Marketable Securities: Valued using quoted prices in active markets for identical assets.
| Description | Level | September 30, 2026 | December 31, 2025 | |||||||||
| As of | ||||||||||||
| Description | Level | September 30, 2026 | December 31, 2025 | |||||||||
| Marketable securities | 1 | $ | $ | |||||||||
| 10 |
(g) Fair Value of Financial Instruments, continued
Marketable securities are classified as available for sale and are valued at fair market value. Maturities of the securities are less than one year.
As
of September 30, 2026 and December 31, 2025, the Company held certain mutual funds, which, under FASB ASC 321-10, were considered equity
investments. As such, the change in fair value in the three months ended September 30, 2026 and 2025 was a gain of $
Gains
resulting from the sales of marketable securities were $
Gains
resulting from the sales of marketable securities were $
Proceeds
from the sales of marketable securities in the nine months ended September 30, 2026 and 2025 were $
Fair Value on a Recurring Basis
The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liabilities and bifurcated embedded derivatives represent Level 3 measurements. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
Schedule of Fair Value Hierarchy of the Valuation Inputs
| As of | ||||||||||||
| Description | Level | September 30, 2026 | December 31, 2025 | |||||||||
| Liabilities | ||||||||||||
| Derivative Liabilities | 3 | $ | $ | |||||||||
| Contingent Consideration Payable | 3 | $ | - | $ | ||||||||
Contingent consideration payables are classified as a Level 3 instrument with significant unobservable inputs. They are considered a non-current liability. See Note 6 below for more information regarding the termination of the LightSolver Licensing Agreement which caused the Contingent Consideration Payable liability noted above to be reduced to $0.
The following table sets forth a summary of the change in the fair value of the derivative liabilities that is measured at fair value on a recurring basis for the nine months ended September 30, 2026 and 2025, respectively:
Summary of Change in Fair Value of Derivative Liabilities
| Description | 2026 | 2025 | ||||||
| Balance on December 31, 2025 and 2024 | $ | $ | ||||||
| Changes in fair value of derivative liabilities | ( | ) | ( | ) | ||||
| Balance on March 31, | $ | |||||||
| Changes in fair value of derivative liabilities | ( | ) | ( | ) | ||||
| Balance on June 30, | $ | $ | - | |||||
| Issuance of derivatives reported at fair value | - | |||||||
| Changes in fair value of derivative liabilities | ( | )- | ||||||
| Balance on September 30, | $ | $ | ||||||
| 11 |
(h) Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” If liability accounting is required, the Company’s derivative instruments are recorded at fair value at the issuance date and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within twelve (12) months of the balance sheet date.
The Company has determined that the Series F Warrants are derivatives that are required to be accounted for as liabilities. The Company has also determined that the following embedded features in the Series F Preferred Shares are not clearly and closely related to the debt host instrument; 1) make-whole interest upon a contingent redemption event; 2) make-whole interest upon a conversion event; 3) an installment redemption upon an Equity Conditions Failure (as defined in the Series F Certificate of Designations (as defined herein)); and 4) variable share-settled installment conversion and as such are bifurcated from the Series F Preferred Shares and accounted for as liabilities. The fair value of the Series F Warrants and embedded features are estimated using internal valuation models. The Company’s valuation models utilize inputs and other assumptions and may not be reflective of the price at which they can be settled.
The Company has determined that the Series F-1 Warrants are derivatives that are required to be accounted for as liabilities. The Company has also determined that the following embedded features in the Series F-1 Preferred Shares are not clearly and closely related to the debt host instrument: 1) make-whole interest upon a contingent redemption event; 2) make-whole interest upon a conversion event; 3) an installment redemption upon an Equity Conditions Failure (as defined in the Series F-1 Certificate of Designation); and 4) variable share-settled installment conversion and as such are bifurcated from the Series F-1 Preferred Shares and accounted for as liabilities. The fair value of the Series F-1 Warrants and embedded features are estimated using internal valuation models. The Company’s valuation models utilize inputs and other assumptions and may not be reflective of the price at which they can be settled.
Warrants
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own Common Stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the Statements of Comprehensive Income (Loss).
Modification of warrants
The Company applies the guidance in ASC 815-40 to account for warrants that are liability classified that are subsequently modified resulting in a reclassification to equity. The warrants are remeasured at fair value on the modification date, the change in fair value is recognized as a non-cash gain or loss on the Statement of Comprehensive Income (Loss), and the warrants are reclassified to additional paid-in capital.
| 12 |
(i) Prepaid Expenses
Prepaid expenses represent expenses paid prior to the date that the related services are rendered or used are comprised principally of prepaid insurance and research and development expenses.
(j) Concentrations
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial institutions and accounts receivable. At times, the Company’s cash in banks exceeds the FDIC insurance limit. The Company has not experienced any loss because of these cash deposits. These cash balances are maintained with two banks as of September 30, 2026.
(k) Risk Management of Cash and Investments
It is the Company’s policy to minimize the Company’s capital resources to investment risks, prioritizing the preservation of capital over investment returns. Investments are maintained in securities, primarily publicly traded, short-term money market funds based on highly rated federal, state and corporate bonds, that minimize the risk to the Company’s capital resources and provide ready access to funds.
The Company’s investment portfolios are regularly monitored for risk and are held with one brokerage firm.
(l) Investments
Investments recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company’s ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for using the cost method to the equity method of valuation in accordance with FASB ASC 323.
In accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company’s ability to significantly influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the time of the investment based upon several factors including, but not limited to the following:
| a) | Representation on the Board of Directors | |
| b) | Participation in policy-making processes | |
| c) | Material intra-entity transactions | |
| d) | Interchange of management personnel | |
| e) | Technological dependencies | |
| f) | Extent of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small. |
The Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the cost method.
(m) Property, Plant and Equipment
Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset.
Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized within “operating income” in the Condensed Consolidated Statements of Operations.
| 13 |
(n) Property, Plant and Equipment, continued
Depreciation is recognized over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of the lease term or their useful lives.
The estimated useful lives for the current and comparative periods are as follows:
Schedule of Estimated Useful Lives of Property Plant and Equipment
| Useful Life | ||
| (in years) | ||
| Plant and equipment | ||
| Furniture and fixtures | ||
| Computer equipment & software | ||
| Leasehold Improvements | Shorter of the remaining lease or estimated useful life |
Depreciation methods, useful lives and residual values are reviewed at each reporting date.
(o) Intangible Assets
The Company’s long-lived intangible assets, other than goodwill, are assessed for impairment when events or circumstances indicate there may be an impairment. These assets were initially recorded at their estimated fair value at the time of acquisition and assets not acquired in acquisitions were recorded at historical cost. However, if their estimated fair value is less than the carrying amount, other intangible assets with indefinite lives are reduced to their estimated fair value through an impairment charge in the Condensed Consolidated Statements of Operations.
Patents and Trade Secrets
Proprietary protection for the Company’s products, technology and process is important to its competitive position. As of September 30, 2026, the Company has issued 19 U.S. patents, 71 foreign patents, and no patent application is pending. The Company also has one foreign patent which has lapsed and 4 foreign patents which have been abandoned. The issued patents are expected to expire between 2036 and 2039. Management intends to protect all other intellectual property (e.g. copyrights, trademarks, and trade secrets) using all legal remedies available to the Company.
The Company records expenses related to the application for and maintenance of patents as a component of research and development expenses on the Condensed Consolidated Statement of Comprehensive Loss.
Patent Costs
Patents may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life and assessed for impairment when necessary.
Other Intangible Assets
Other intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization and accumulated impairment losses.
Amortization
Amortization is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use. The estimated useful lives for the current and comparative periods are as follows:
Schedule of Estimated Useful lives of Intangible Assets
| Useful Life | ||
| (in years) | ||
| Patents and trademarks |
| 14 |
(p) Goodwill
Goodwill is evaluated annually for impairment or whenever the Company identifies certain triggering events or circumstances that would more likely than not reduce the fair value below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include, among other things, unexpected adverse business conditions, economic factors (for example, the loss of key personnel), supply costs, unanticipated competitive activities, and acts by governments and courts.
Goodwill associated with the legacy business was evaluated as of September 30, 2026 due to the change in the Company’s stock price, which could be viewed as a triggering event. Management views the reduction in the Company’s stock price as temporary. As of this measurement date, no impairment was required.
(q) Recoverability of Long-Lived Assets
In accordance with FASB ASC 360-10-35 “Impairment or Disposal of Long-lived Assets”, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment.
The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges) and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets.
(r) Right-of-Use Assets
The
Company leased a facility in Baltimore, Maryland under an operating lease (“2024 Baltimore Lease”) with annual rentals of
$
The
Company began subleasing a facility in San Franscisco, California under an operating lease (“333 Bush Street Lease”) with
a monthly rent of $
In accordance with FASB ASC, Topic 842, Leases (“ASC 842”), which increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as lease assets and lease liabilities. The guidance requires the recognition of the right-of-use (“ROU”) assets and related operating and finance lease liabilities on the balance sheet.
The Company utilizes the package of practical expedients permitted within the standard, which allows an entity to forgo reassessing (i) whether a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has also elected the short-term lease accounting policy under which the Company would not recognize a lease liability or ROU asset for any lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that the Company is more than reasonably certain to exercise.
| 15 |
(r) Right-of-Use Assets, continued
For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The Company generally uses its incremental borrowing rate as the discount rate for leases, unless an interest rate is implicitly stated in the lease. The present value of the lease payments is calculated using the incremental borrowing rate for operating leases, which was determined using a portfolio approach based on the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term. The lease term for all the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend the lease that the Company is reasonably certain to exercise, or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment.
Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term.
The Company’s operating leases are comprised of the 333 Bush Street Lease on the Condensed Consolidated Balance Sheets. The information related to these leases is presented below.
Schedule of Condensed Consolidated Balance Sheet Information Related to Operating Lease
| Balance Sheet Location | Lease | Lease | Total | Lease | Lease | Total | ||||||||||||||||||
| As of September 30, 2026 | As of December 31, 2025 | |||||||||||||||||||||||
| 2024 Baltimore | 333 Bush Street | 2024 Baltimore | 333 Bush Street | |||||||||||||||||||||
| Balance Sheet Location | Lease | Lease | Total | Lease | Lease | Total | ||||||||||||||||||
| Operating Lease | ||||||||||||||||||||||||
| Lease Right of Use | $ | - | $ | $ | $ | - | $ | - | $ | - | ||||||||||||||
| Lease Payable, current | - | - | - | - | ||||||||||||||||||||
| Lease Payable - net of current | - | - | - | - | ||||||||||||||||||||
The following provides details of the Company’s lease expense:
Schedule of Lease Expense
| Lease Expenses | Lease | Lease | Total | Lease | Lease | Total | ||||||||||||||||||
For the Three Months Ended September 30, 2026 | For the Three Months Ended September 30, 2025 | |||||||||||||||||||||||
| 2024 Baltimore | 333 Bush Street | 2024 Baltimore | 333 Bush Street | |||||||||||||||||||||
| Lease Expenses | Lease | Lease | Total | Lease | Lease | Total | ||||||||||||||||||
| Operating Leases | ||||||||||||||||||||||||
| Lease Costs | $ | - | $ | $ | $ | - | $ | - | $ | - | ||||||||||||||
| Lease Expenses | Lease | Lease | Total | Lease | Lease | Total | ||||||||||||||||||
For the Nine Months Ended September 30, 2026 | For the Nine Months Ended September 30, 2025 | |||||||||||||||||||||||
| 2024 Baltimore | 333 Bush Street | 2024 Baltimore | 333 Bush Street | |||||||||||||||||||||
| Lease Expenses | Lease | Lease | Total | Lease | Lease | Total | ||||||||||||||||||
| Operating Leases | ||||||||||||||||||||||||
| Lease Costs | $ | - | $ | $ | $ | $ | - | $ | ||||||||||||||||
| 16 |
(r) Right-of-Use Assets, continued
Other information as of September 30, 2026, related to leases is presented below:
Schedule of Other Lease Information
| 2024 Baltimore | 333 Bush Street | |||||||||||
| Balance Sheet Location | Lease | Lease | Total | |||||||||
| Operating Leases | ||||||||||||
| Operating cash used | $ | - | $ | $ | ||||||||
| Weighted average remaining lease term (in years) | - | |||||||||||
| Discount rate | % | % | % | |||||||||
Operating
cash used for the 2024 Baltimore Lease during the nine months ended September 30 2025, was $
(s) Income Taxes
The Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company’s assets and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.
The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management’s opinion, adequate provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.
Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for “unrecognized tax benefits” is recorded for any tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of September 30, 2026 and December 31, 2025, no liability for unrecognized tax benefits was required to be reported.
There was no income tax benefit recorded for the losses for the three and nine months ended September 30, 2026 and 2025 since management determined that the realization of the net deferred tax assets is not more likely than not to be realized and has recorded a full valuation allowance on the net deferred tax assets.
The
Company’s policy for recording interest and penalties associated with tax audits is to record such items as a component of general
and administrative expense. There were
The Company files U.S. federal income tax returns and state income tax returns. Since the Company had losses in the past, all prior years that generated net operating loss carryforwards are open and subject to audit examination in relation to the net operating loss generated from those years.
| 17 |
(t) Basic and Diluted Earnings per Share of Common Stock
Basic earnings per Common Stock is based on the weighted average number of shares outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of Common Stock plus dilutive Common Stock equivalents outstanding during the period. Potential shares of Common Stock that would have the effect of increasing diluted earnings per share are considered anti-dilutive.
Diluted net loss per share is computed using the weighted average number of shares of Common Stock and dilutive potential Common Stock outstanding during the period.
As the Company reported a net loss for the three and nine months ended September 30, 2026 and 2025, Common Stock equivalents were anti-dilutive.
For the three and nine months ended September 30, 2026 and 2025, the following securities are excluded from the calculation of weighted average dilutive Common Stock because their inclusion would have been anti-dilutive.
Schedule of Weighted Average Number of Shares Outstanding Earnings Per Share
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Stock Options | ||||||||||||||||
| Unvested Restricted Stock Units | ||||||||||||||||
| Warrants to purchase Common Stock | ||||||||||||||||
| Series D Convertible Preferred Stock | ||||||||||||||||
| Series G Convertible Preferred Stock | ||||||||||||||||
| Series H Convertible Preferred Stock | ||||||||||||||||
| Series I Convertible Preferred Stock | - | - | ||||||||||||||
| Total potentially dilutive shares | ||||||||||||||||
| 18 |
(u) Stock-based Payments
The Company accounts for stock-based compensation under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, “Compensation - Stock Compensation”, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (“Topic 718”), Improvements to Nonemployee Share-Based Payment Accounting (the “2018 Update”). The amendments in the 2018 Update expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. Prior to the 2018 Update, Topic 718 applied only to share-based transactions to employees. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied.
The Company has elected to account for forfeiture of stock-based awards as they occur.
(v) Research and Development Costs
In accordance with FASB ASC 730, research and development costs are expensed as incurred and consist of fees paid to third parties that conduct certain research and development activities on the Company’s behalf.
(w) Recently Issued Accounting Pronouncements
As of September 30, 2026, and for the three and nine months then ended, there were no recently issued accounting pronouncements that had a material effect on the Company’s consolidated financial statements.
In April 2026, the Financial Accounting Standards Board (“FASB”) issued ASU 2026-01, “Equity (Topic 505): Initial Measurement of Paid-in-Kind Dividends on Equity-Classified Preferred Stock”. The update provides authoritative guidance on the initial measurement of paid-in-kind (“PIK”) dividends on equity-classified preferred stock and requires such dividends to be measured based on the stated PIK dividend rate and applicable liquidation preference specified in the related preferred stock agreement. The amendments are effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that adoption of ASU 2026-01 will have on its financial statements and related disclosures. The Company has not yet adopted this standard.
In May 2026, the FASB issued ASU 2026-02, Environmental Credits and Environmental Credit Obligations (Topic 818). The standard establishes a comprehensive accounting framework for the recognition, measurement, presentation and disclosure of environmental credits and environmental credit obligations. The guidance applies to entities that generate, purchase, receive or hold environmental credits and entities that are subject to environmental compliance obligations that may be settled using such credits. Among other provisions, the standard establishes accounting models for environmental credit assets and related environmental credit obligation liabilities. The Company is evaluating the impact of the new guidance. Based on its current operations, the Company does not expect adoption of ASU 2026-02 to have a material impact on its condensed consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses”, which requires enhanced disclosures of specified natural expense categories included within relevant income statement captions. The standard is intended to improve transparency by requiring disaggregation of expenses such as employee compensation, depreciation, and amortization in tabular format within the notes to the financial statements. The amendments in ASU 2024-03 are effective for fiscal years beginning after December 15, 2026, and interim periods thereafter. Early adoption is permitted. The Company expects that adoption will primarily impact the presentation and disclosure of expenses and is currently evaluating the effect of this guidance on its disclosures.
In September 2026, the FASB issued ASU 2026-03, Fair Value Measurement (Topic 820): Investment Companies with Equity Securities Subject to Contractual Sale Restrictions. The Company evaluated the guidance and determined that it is not applicable to the Company’s operations because the Company is not an investment company and does not apply ASC 946, Financial Services—Investment Companies.
Note 3 – Recent Developments, Liquidity and Management’s Plans
As of September 30, 2026, the Company’s cash
on hand was $
During
the year ended December 31, 2025, the Company raised $
The Company evaluated the current cash requirements for operations in conjunction with management’s strategic plan and believes that the Company’s current financial resources as of the date of the issuance of these condensed consolidated financial statements are sufficient to fund its current operating budget and contractual obligations as of September 30, 2026 as they fall due within the next twelve-month period, alleviating any substantial doubt raised by the Company’s historical operating results and satisfying its estimated liquidity needs for twelve months from the issuance of these condensed consolidated financial statements.
| 19 |
Note 4 – Trade and Other Payables
Trade and other payables consist of the following:
Schedule of Trade and Other Payables
| September 30, 2026 | December 31, 2025 | |||||||
| Accounts Payable – Trade | $ | $ | ||||||
| Accrued Expenses | ||||||||
| Trade and other payables, Total | $ | $ | ||||||
Note 5 – Property and Equipment, Net
The major classifications of property and equipment, including their estimated useful lives, are summarized as follows at the balance sheet dates:
Schedule of Property and Equipment Estimated Useful Lives
| Estimated Useful Life | ||||||||||
| (Years) | September 30, 2026 | December 31, 2025 | ||||||||
| Computer equipment | $ | - | ||||||||
| Less: Accumulated depreciation | ( | ) | - | |||||||
| Total property and equipment, net | $ | $ | - | |||||||
For
the three months ended September 30, 2026 and 2025, depreciation expense relating to property and equipment amounted to $
For
the nine months ended September 30, 2026 and 2025, depreciation expense relating to property and equipment amounted to $
Note 6 – LightSolver Technology License Termination
On June 26, 2026, the Company provided notice of its intention to terminate the Technology License and Development Agreement, dated as of September 2, 2025 (the “License Agreement”), by and among LightSolver, LPU Holdings LLC (“LPU”), a wholly owned subsidiary of the Company, and, solely with respect to certain provisions of the License Agreement, the Company, effective as of June 26, 2026. The License Agreement had granted LPU an exclusive license (the “Exclusive License”) to use and commercialize LightSolver’s proprietary laser processing hardware units and related proprietary technology for cryptocurrency mining applications, which the Company had determined to be an indefinite-lived intangible asset not subject to amortization. In connection with the Termination, LPU was automatically and immediately relieved from its obligation to make any additional milestone payments to LightSolver, and LightSolver has no right to receive any further contingent consideration thereunder. As a result of the Termination, the Company recorded an impairment charge with respect to the Exclusive License, which is reflected as “Impairment of Technology License” within the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2026.
Note 7 – Stock-based Payments
Equity incentive Plans
2017 Stock Incentive Plan
On
August 7, 2017, the Company’s stockholders approved, and the Company adopted the 2017 Stock Incentive Plan (“2017 Plan”).
The 2017 Plan provides for the issuance of up to
2018 Stock Incentive Plan
On
December 7, 2018, the Company’s stockholders approved, and the Company adopted the 2018 Stock Incentive Plan (“2018 Plan”).
On August 27, 2020, the 2018 Plan was modified to increase the total authorized shares available for future issuance. The 2018 Plan,
as amended, provides for the issuance of up to
| 20 |
2021 Stock Incentive Plan
On
April 15, 2021, the Company’s stockholders approved, and the Company adopted the 2021 Stock Incentive Plan, (as amended the “2021
Plan”). The 2021 Plan provides for the issuance of up to
Stock Options
The following table summarizes the activities for the Company’s stock options for the nine months ended September 30, 2026:
Summary of Stock Option Activity
| Weighted | ||||||||||||||||||||
| Average | ||||||||||||||||||||
| Weighted | Weighted | Remaining | ||||||||||||||||||
| Number | Average | Average | Contractual | Aggregate | ||||||||||||||||
| of | Exercise | Grant Date | Term | Intrinsic | ||||||||||||||||
| Shares | Price | Fair Value | (years) | Value | ||||||||||||||||
| Balance at December 31, 2025 | $ | $ | $ | - | ||||||||||||||||
| Granted | - | |||||||||||||||||||
| Exercised | - | - | - | - | - | |||||||||||||||
| Forfeited | ( | ) | - | |||||||||||||||||
| Canceled/Expired | ( | ) | - | |||||||||||||||||
| Balance September 30, 2026 | $ | - | ||||||||||||||||||
| Exercisable as of September 30, 2026 | $ | - | ||||||||||||||||||
The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $
During
the three months ended September 30, 2026 and 2025, the Company recognized stock option expenses totaling $
The
unamortized stock option expenses as of September 30, 2026 totaled $
Restricted Stock Units
On
October 14, 2021, the Compensation Committee of the Board of Directors approved grants totaling
| ● | ||
| ● | ||
| ● | ||
| ● |
| 21 |
As of September 30, 2026 and 2025, none of the vesting milestones have been met, respectively.
On
October 2, 2025, the Compensation Committee of the Board of Directors approved grants totaling
The Compensation Committee of the Board of Directors approved several RSU grants to various consultants, an employee and a new board member in 2026. All issued RSUs have either vested or were forfeited. These RSUs were granted under the 2021 Plan
The following is the status of outstanding unvested RSUs outstanding as of September 30, 2026 and the changes for the nine months ended September 30, 2026:
Summary of Restricted Stock Units Activity
| Weighted | ||||||||
| Average | ||||||||
| Number of | Grant Date | |||||||
| RSUs | Fair Value | |||||||
| Balance at December 31, 2025 | $ | |||||||
| Share Adjustment | ||||||||
| Granted | ||||||||
| Vested | ( |
) | ||||||
| Forfeited | ( |
) | ||||||
| Canceled/Expired | - | - | ||||||
| Balance at September 30, 2026 | - | $ | - | |||||
As
of September 30, 2026, the unamortized value of the RSUs was $
Note 8 – Stock-based Compensation Expenses
Income Tax Gross-up Payments
As noted previously, on October 2, 2025, the Compensation Committee of the Board of Directors approved grants totaling
Note 9 – Equity
Authorized Capital Stock
At
the Company’s annual meeting of stockholders, held on June 3, 2025, which was reconvened from May 20, 2025, the Company’s
stockholders approved an amendment to the Company’s Certificate of Incorporation (the “Share Increase Amendment”) to
increase the number of authorized shares of Common Stock from
As
of September 30, 2026, the Company’s authorized capital stock consisted of
As
of September 30, 2026 and December 31, 2025, there were
Preferred Stock
The holders of preferred shares or preferred warrants are entitled to vote, as determined and as limited by the certificate of designation for each class of preferred shares or warrants, at meetings of the Company stockholders.
| 22 |
Series D Convertible Preferred Stock
The following are the principal terms of the Series D Preferred Stock:
Rank
The Series D Preferred Stock ranks (1) on parity with Common Stock on an “as converted” basis, (2) senior to any series of the Company’s capital stock hereafter created specifically ranking by its terms junior to the Series D Preferred Stock, (3) on parity with any series of the Company’s capital stock hereafter created specifically ranking by its terms on parity with the Series D Preferred Stock, and (4) junior to any series of the Company’s capital stock hereafter created specifically ranking by its terms senior to the Series D Preferred Stock in each case, as to dividends or distributions of assets upon the Company’s liquidation, dissolution or winding up whether voluntary or involuntary.
Conversion Rights
A
holder of Series D Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series D Preferred Stock
into shares of the Company’s Common Stock, determined by dividing the stated value equal to $
Dividend Rights
In addition to stock dividends or distributions for which proportionate adjustments will be made, holders of Series D Preferred Stock are entitled to receive dividends on shares of Series D Preferred Stock equal, on an as-if-converted-to-common-stock basis, to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends are payable on shares of Series D Preferred Stock.
Voting Rights
Subject to the Series D Beneficial Ownership Limitation, on any matter presented to the Company’s stockholders for their action or consideration at any meeting of the Company’s stockholders (or by written consent of stockholders in lieu of a meeting), each holder, in its capacity as such, shall be entitled to cast the number of votes equal to the number of whole shares of the Company’s Common Stock into which the Series D Preferred Stock beneficially owned by such holder are convertible as of the record date for determining stockholders entitled to vote on or consent to such matter (taking into account all Series D Preferred Stock beneficially owned by such holder). Except as otherwise required by law or by the other provisions of the Certificate of Designation of Series D Convertible Preferred Stock (the “Series D Certificate of Designation”), the holders of Series D Preferred Stock, in their capacity as such, shall vote together with the holders of the Company’s Common Stock and any other class or series of stock entitled to vote thereon as a single class.
| 23 |
Liquidation Rights
Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series D Preferred Stock are entitled to receive, pari passu with the holders of Common Stock, out of the assets available for distribution to stockholders an amount equal to such amount per share as would have been payable had all shares of Series D Preferred Stock been converted into Common Stock immediately before such liquidation, dissolution or winding up, without giving effect to any limitation on conversion as a result of the Series D Beneficial Ownership Limitation, as described above.
Exchange Listing
Series D Preferred Stock is not listed on the Nasdaq, any national securities exchange or other nationally recognized trading system. The Company’s Common Stock issuable upon conversion of the Series D Preferred Stock is listed on the Nasdaq under the symbol “QCLS”.
Failure to Deliver Conversion Shares
Compensation for Series D Buy-In on Failure to Timely Deliver Shares
If the Company fails to timely deliver the Series D Conversion Shares to the holder, and if after the required delivery date the holder is required by its broker to purchase (in an open market transaction or otherwise) or the holder or its brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the holder of the Series D Conversion Shares which the holder anticipated receiving upon such conversion or exercise (a “Series D Buy-In”), then the Company is obligated to (A) pay in cash to such holder (in addition to any other remedies available to or elected by such holder) the amount, if any, by which (x) such holder’s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of Series D Conversion Shares that such holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such holder, either reissue (if surrendered) the shares of Series D Preferred Stock equal to the number of shares of Series D Preferred Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such holder the number of Series D Conversion Shares that would have been issued if the Company had timely complied with its delivery requirements.
As
of September 30, 2026 and December 31, 2025, the Company had
Series F Convertible Preferred Stock
On
February 21, 2023, the Company entered into a Securities Purchase Agreement (the “Series F Purchase Agreement”) with certain
accredited investors (the “Series F Investors”), pursuant to which it agreed to sell to the Investors (i) an aggregate of
The
Series F Preferred Stock were fully converted during the three months ended September 30, 2025. The derivative liability is
reclassified to equity upon final conversion. Since the derivative had a fair value of $
| 24 |
Series F-1 Preferred Stock
On
May 20, 2024, the Company entered into a Securities Purchase Agreement (the “Series F-1 Purchase Agreement”) with certain
accredited investors (the “Series F-1 Investors”) pursuant to which it agreed to sell to the Series F-1 Investors (i) an
aggregate of
The Series F-1 Preferred Stock were fully
converted during the three months ended September 30, 2025. The derivative liability was reclassified to equity upon final
conversion. Since the derivative had a fair value of $
Series G Preferred Stock
On
May 20, 2024, the Company entered into a Securities Purchase Agreement (the “Series G Purchase Agreement” and collectively
with the Series F-1 Purchase Agreement, each a “Purchase Agreement” and collectively, the “Purchase Agreements”)
with certain accredited investors (the “Series G Investors” and collectively with the Series F-1 Investors, the “Investors”),
with certain accredited investors (the “Series G Investors”), pursuant to which it agreed to sell to the Series G Investors
(i) an aggregate of
| 25 |
On
April 17, 2025, in connection with the issuance of stock options to certain officers of the Company, (i) the Series G Conversion Price
was equal to $
At any time after the issuance date of the Series G Preferred Shares, the Company has the option to redeem in cash all or any portion of the shares of Series G Preferred Shares then outstanding at a premium upon notice by the Company to all holders of the Series G Preferred Shares.
The
holders of the Series G Preferred Shares will be entitled to dividends of
During
the three months ended September 30, 2026 and 2025, the Company recorded dividends totaling $
Notwithstanding the foregoing, the Company’s ability to settle conversions and make dividend make-whole payments using shares of Common Stock is subject to certain limitations set forth in the Series G Certificate of Designations. Further, the Series G Certificate of Designations contains a certain beneficial ownership limitation, which applies to each Series G Investor, other than PharmaCyte Biotech, Inc., after giving effect to the issuance of shares of Common Stock issuable upon conversion of the Series G Preferred Shares or as part of any dividend make-whole payment under the Series G Certificate of Designations.
Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, each holder of shares of the Series G Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount per share of Series G Preferred Stock equal to the greater of (A) 125% of the stated value of such share of Series G Preferred Stock (plus any applicable make-whole amount, unpaid late charge or other applicable amount) on the date of such payment and (B) the amount per share such holder would receive if such holder converted such share of Series G Preferred Stock into Common Stock immediately prior to the date of such payment. All shares of capital stock of the Company shall be junior in rank to all shares of Series G Preferred Stock with respect to the preferences as to payments upon liquidation.
On
June 17, 2024, the Company entered into an Amendment Agreement (the “Series G Amendment”) with the Required Holders (as defined
in the Series G Certificate of Designations). Pursuant to the Series G Amendment, the Required Holders agreed to amend the Series G Certificate
of Designations by filing a Certificate of Amendment (“Series G Certificate of Amendment”) to the Series G Certificate of
Designations with the Secretary of State of the State of Delaware (the “Secretary of State”) to increase the number of authorized
shares of Series G Preferred Stock from
| 26 |
The shares Series G Preferred Stock are classified as temporary equity as the holders of the Series G Preferred Stock have the right to require the Company to redeem for cash all or any portion of each such holder’s shares upon the suspension from trading or the failure of the Common Stock to be trading or listed (as applicable) on an eligible trading market for a period of five (5) consecutive trading days. The Series G Preferred Stock is not unconditionally redeemable and is only conditionally puttable at the holder’s option upon this trading suspension or failure. This would not be considered to be within the Company’s control.
The
estimated fair value of the Series G Preferred Stock on the issuance date of approximately $
The
approximately $
Since
the fair value of the liabilities required to be subsequently measured at fair value exceeds the net proceeds received, the excess of
the fair value over the net proceeds received is recognized as a loss in earnings. As such, the Company recognized a loss on the issuance
of preferred stock of approximately $
On August 8, 2024, the Company entered into an Amendment Agreement (the “August Series G Amendment”) with the Required Holders (as defined in the Series G Certificate of Designations). Pursuant to the August Series G Amendment, the Required Holders agreed to amend the Series G Certificate of Designations by filing a Certificate of Amendment (“August Series G Certificate of Amendment”) to the Series G Certificate of Designations with the Secretary of State to adjust the calculation of the PIK Shares. On August 8, 2024, the Company filed the August Series G Certificate of Amendment with the Secretary of State, thereby amending the Series G Certificate of Designations. The August Series G Certificate of Amendment became effective with the Secretary of State upon filing.
During the three months ended September 30, 2026, the Company did not issue any shares of Series G Preferred Stock
in lieu of dividends. During the nine months ended September 30, 2026, the Company issued
During the three months ended September 30, 2025,
the Company issued
Series H Preferred Stock
On
September 2, 2025, the Company entered into a Securities Purchase Agreement (the “Series H Purchase Agreement”) with certain
accredited investors (the “Series H Investors”) pursuant to which it agreed to sell to the Series H Investors (i) an aggregate
of
The
Series H Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and
subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable
for Common Stock, at a price below the then-applicable Series H Conversion Price (subject to certain exceptions). In September 2025,
in connection with the 2025 Reverse Stock Split and pursuant to the full ratchet anti-dilution provisions contained in the Series H Certificate
of Designations, the Series H Conversion Price was reduced to $
| 27 |
The
holders of the Series H Preferred Stock are entitled to dividends of
During
the three months ended September 30, 2026 and 2025, the Company recorded dividends totaling $
Notwithstanding the foregoing, the Company’s ability to settle conversions is subject to certain limitations set forth in the Series H Certificate of Designations, including a limit on the number of shares that may be issued until the time, if any, that the Company’s stockholders have approved the issuance of more than 19.99% of the Company’s outstanding shares of Common Stock in accordance with Nasdaq listing standards (the “September 2025 Stockholder Approval”). The September 2025 Stockholder Approval was obtained on November 14, 2025 at a special meeting of stockholders of the Company. Further, except with respect to Pharmacyte, the Series H Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the issuance of shares of Common Stock issuable upon conversion of the Series H Preferred Stock or exercise of the Series H Warrants.
The
shares of Series H Preferred Stock were determined to be more akin to a debt-like host than an equity-like host. The Company identified
the following embedded features that are not clearly and closely related to the debt host instrument: 1) certain contingent redemption
options, 2) optional conversion features inclusive of make-whole interest and 3) an increase in the dividend rate related to the occurrence
of a triggering event. These features were bundled together, assigned probabilities of being affected and measured at fair value. Subsequent
changes in fair value of these features are recognized in the Consolidated Statement of Operations. The Company estimated the $
The
discount to the fair value is included as a reduction to the carrying value of the Series H Preferred Stock. On September 30, 2025, the
Company recorded a total discount of $
In connection with the Series H Private Placement, the Company and the Series H Investors entered into that certain Registration Rights Agreement, dated as of September 2, 2025 (the “Series H Registration Rights Agreement,” and, together with the Series H Purchase Agreement, the Series H Certificate of Designations, and the Series H Warrants, the “Transaction Documents”), pursuant to which, the Company agreed to, among other things, prepare and file with the SEC a registration statement (the “Series H Registration Statement”) covering the resale of all of the Registrable Securities (as defined in the Series H Registration Rights Agreement) prior to the applicable Filing Deadline (as defined in the Series H Registration Rights Agreement).
On September 30, 2025, the Company entered into an Omnibus Waiver and Amendment (the “September 2025 Amendment”) with the Required Holders (as defined in the Series H Certificate of Designations). Pursuant to the Amendment, the Required Holders agreed (A) to amend (i) the Series H Certificate of Designations, as described below, by filing a Certificate of Amendment (“September 2025 Certificate of Amendment”) to the Series H Certificate of Designations with the Secretary of State, (ii) the Series H Purchase Agreement to amend the definition of “Excluded Securities” such that the definition includes the issuance of Common Stock issued after the date of the Series H Purchase Agreement pursuant to an Approved Stock Plan (as defined in the Series H Purchase Agreement) which in the aggregate does not exceed more than 15.0% of the sum of (x) shares of Common Stock issued and outstanding as of the date of the Series H Purchase Agreement, and (y) the shares of Common Stock issuable upon conversion of certain of the Company’s outstanding shares of preferred stock (the “Excluded Securities Modification”), and (iii) the Series H Registration Rights Agreement such that the Series H Registration Statement is required to be filed with the SEC by the date that is 30 calendar days following the Series H Closing Date and (B) waive (i) any prohibitions or limitations under the Transaction Documents in connection with the issuance by the Company of certain warrants to purchase Common Stock to certain current and future consultants of the Company, (ii) any prohibitions or limitations under the Transaction Documents in connection with the registration of certain securities of the Company, and (iii) any failure by the Company to file the Series H Registration Statement by the Filing Deadline.
The September 2025 Certificate of Amendment amends the Series H Certificate of Designations to amend the definition of “Excluded Securities” substantially similar to the Excluded Securities Modification. On October 3, 2025, the Company filed the September 2025 Certificate of Amendment with the Secretary of State, thereby amending the Series H Certificate of Designations. The September 2025 Certificate of Amendment became effective with the Secretary of State upon filing.
See Note 16 for a subsequent amendment extending the maturity date of the Series H Preferred Stock conversion.
| 28 |
Common Stock
As
of September 30, 2026, the Company had
During
the three and nine months ended September 30, 2026, the Company issued
Common Stock Warrants
The table below summarizes the warrant activity for the nine months ended September 30, 2026:
Summary of Warrant Activity
| Weighted | Average | |||||||||||||||
| Average | Remaining | Aggregate | ||||||||||||||
| Number of | Exercise | Contractual | Intrinsic | |||||||||||||
| Warrants | Price | Term (years) | Value | |||||||||||||
| Balance at December 31, 2025 | $ | $ | ||||||||||||||
| Issued | - | |||||||||||||||
| Exercised | ( | ) | - | - | ||||||||||||
| Forfeited | ( | ) | - | - | ||||||||||||
| Canceled/Expired | ( | ) | - | - | ||||||||||||
| Balance at September 30, 2026 | $ | $ | - | |||||||||||||
| Exercisable as of September 30, 2026 | $ | $ | - | |||||||||||||
The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price
of $
On
April 17, 2025, in connection with the issuance of Stock Options, (i) the Series F Conversion Price, Series F-1 Conversion Price and
Series G Conversion Price was adjusted to $
| 29 |
Series F Common Stock Warrants
Pursuant
to the February 2023 Offering, the Company issued to investors the Series F Warrants to purchase
Following
the 2024 Reverse Stock Split, the exercise price of the Series F Warrants was reduced to $
The Series F Warrants were initially accounted for as liabilities based on the following analysis:
The
Series F Warrants were determined to be within the scope of ASC 480-10 as they are puttable to the Company at the Holders’ election
upon the occurrence of a Fundamental Transaction (as defined in the agreements). As such, the Company recorded the Series F Warrants
as a liability at fair value with subsequent changes in fair value recognized in earnings. The Company utilized the Black Scholes Model
to calculate the value of these warrants. The fair value of the Series F Warrants of $
Transaction
costs incurred attributable to the issuance of the Series F Warrants of $
Series F-1 Warrants
Pursuant
to the Series F-1 Private Placement, the Company issued to investors (i) the Series F-1 Long-Term Warrants to purchase
On
April 17, 2025, in connection with the issuance of stock options to certain officers of the Company and pursuant to the full ratchet
anti-dilution provisions contained in the Series F-1 Warrants, the exercise price of the Series F-1 Warrants was reduced to $
| 30 |
Pursuant
to the April 2025 Amendment Agreement, the Series F-1 Short-Term Warrants were extended to expire
The
Series F-1 Preferred Shares were determined to be more akin to a debt-like host than an equity-like host. The Company identified the
following embedded features that are not clearly and closely related to the debt host instrument: 1) make-whole interest upon a contingent
redemption event, 2) make-whole interest upon a conversion event, 3) an installment redemption upon an Equity Conditions Failure (as
defined in the Series F-1 Certificate of Designations), and 4) variable share-settled installment conversion. These features were bundled
together, assigned probabilities of being affected and measured at fair value. Subsequent changes in fair value of these features are
recognized in the Consolidated Statements of Operations. The Company estimated at issuance the $
Series G Warrants
Pursuant
to the Series G Private Placement, the Company issued to investors (i) the Series G Long-Term Warrants to purchase
The exercise price of the Series G Warrants and the number of shares issuable upon exercise of the Series G Warrants are subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment, on a “full ratchet” basis, in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable exercise price (subject to certain exceptions). Upon any such price-based adjustment to the exercise price, the number of shares issuable upon exercise of the Series G Warrants will be increased proportionately.
On
April 17, 2025, in connection with the issuance of stock options to certain officers of the Company and pursuant to the full ratchet
anti-dilution provisions contained in the Series G Warrants, the exercise price of the Series G Warrants was reduced to $
The
Series G Preferred Shares were determined to be more akin to a debt-like host than an equity-like host. The Company identified the following
embedded features that are not clearly and closely related to the debt host instrument: 1) make-whole interest upon a contingent redemption
event, 2) make-whole interest upon a conversion event, 3) an installment redemption upon an Equity Conditions Failure (as defined in
the Series G Certificate of Designations), and 4) variable share-settled installment conversion. These features were bundled together,
assigned probabilities of being affected and measured at fair value. Subsequent changes in fair value of these features are recognized
in the Consolidated Statements of Operations. The Company estimated at issuance the $
During the three and nine months ended September 30, 2026, there were no exercises of Series G Short-Term Warrants.
During
the three months ended September 30, 2025, holders of Series G Short-Term Warrants exercised
| 31 |
Series H Warrants
Pursuant
to the Series H Private Placement, the Company issued investors the Series H Warrants to purchase
Note 10 – Commitments and Contingencies
Consulting Agreement with James Altucher and Z-List Media
On October 1, 2025, the Company entered into a consulting agreement (the “Altucher Consulting Agreement”) with James Altucher and Z-List Media, Inc. (collectively, the “Consultants”), pursuant to which, the Consultants agreed to provide certain consulting services to the Company, including fund raising, crypto portfolio management, investor relations, strategic planning, deal flow analysis, introductions to further its business goals, advice related to sector growth initiatives and any other consulting or advisory services which the Company reasonably requests that the Consultants provide to the Company. The Altucher Consulting Agreement has a term of two years unless earlier terminated pursuant to the terms of the Altucher Consulting Agreement or upon the mutual written consent of the Company and the Consultants in accordance with the terms of the Altucher Consulting Agreement.
Pursuant
to the Altucher Consulting Agreement, the Company agreed to issue to Z-List Media, Inc. warrants to purchase up to an aggregate of
Litigation and Settlements
Raymond Akers Actions
On April 14, 2021, Raymond F. Akers, Jr., Ph.D. filed a lawsuit against the Company (f/k/a Akers Biosciences, Inc.) in the Superior Court of New Jersey, Law Division, Gloucester County (the “First Raymond Akers Action”). Dr. Akers asserts one common law whistleblower retaliation claim against the Company.
On September 23, 2021, the Court granted the Company’s Motion to Dismiss Plaintiff’s Amended Complaint and dismissed Plaintiff’s Amended Complaint. The Court indicated that Dr. Akers is “free to file another complaint, however, tort-based ‘Pierce’ allegations, and/or CEPA claims are barred by the statute of limitations.”
| 32 |
On March 1, 2022, Dr. Akers filed a second action against the Company in the Superior Court of New Jersey, Law Division, Gloucester County (the “Second Raymond Akers Action”) again asserting one common law whistleblower retaliation claim against the Company. The Company believes that the Second Raymond Akers Action was filed against the Court’s specific admonition that Plaintiff does not attempt to circumvent the statute of limitations.
On May 27, 2022, the Court granted-in-part and denied-in-part the Company’s Motion to Dismiss Plaintiff’s Complaint. The Court reaffirmed the ruling in the First Raymond Akers Action that any tort-based Pierce claims are time-barred. However, the Court denied the Motion as it pertained to Plaintiff’s contract-based Pierce claim and “Repayment of Monies Owed” claim. On July 29, 2022, the Company filed its Answer, which included affirmative defenses.
On April 29, 2025, the complaint was confidentially settled between the parties. There was no material impact on the Company’s financial condition or the results of operations. All legal fees incurred were expensed as and when incurred.
Note 11 – Related Parties
Consulting Agreement with Chelsea Voss
On January 16, 2026, the Company entered into a consulting agreement (the “Voss Consulting Agreement”) with Chelsea Voss, then a member of the Company’s Board of Directors, pursuant to which, Ms. Voss agreed to provide certain consulting services to the Company, including evaluating companies and making related introductions, analyzing technologies and operations, reviewing and advising on potential acquisitions and any other consulting or advisory services which the Company reasonably requests that Ms. Voss provide to the Company. The Voss Consulting Agreement had a term of twelve (12) months, unless earlier terminated pursuant to the terms of the Voss Consulting Agreement or upon the mutual written consent of the Company and Ms. Voss in accordance with the terms of the Voss Consulting Agreement.
Pursuant
to the Voss Consulting Agreement, Ms. Voss was entitled to a monthly fee equal to $
On September 10, 2026, the Company and Ms. Voss mutually terminated, effective immediately, the Voss Consulting Agreement, which was originally reported on the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on January 23, 2026. Also on September 10, 2026, Ms. Voss resigned as a member of the Company’s Board of Directors. In connection with the termination, the unvested portions of the restricted stock units and Consultant Options granted to Ms. Voss were forfeited.
Upon termination of the consulting agreement with Chelsea Voss on September 10, 2026, the Company accelerated recognition of the remaining unrecognized compensation expense associated with the vested restricted stock units and stock options. Accordingly, the Company recognized a one-time stock-based compensation charge during the three months ended September 30, 2026, related to the acceleration and ceased recognizing compensation expense related to the forfeited awards and warrants.
Consulting Agreement with Ocean Avenue
On September 10, 2026, the Company and Ocean Avenue Holdings LLC mutually
terminated, effective immediately, the consulting agreement, which was originally reported on the Company’s Current Report on Form
8-K filed with the SEC on December 9, 2025. In connection with the termination, the unvested portions of the warrants and restricted shares
issued to Ocean Avenue Holdings LLC (
Upon termination of the consulting agreement with Ocean Avenue Holdings LLC on September 10, 2026, the Company accelerated recognition of the remaining unrecognized compensation expense associated with the vested restricted stock awards and warrants. Accordingly, the Company recognized a one-time stock-based compensation charge during the three months ended September 30, 2026, related to the acceleration and ceased recognizing compensation expense related to the forfeited awards and warrants.
SRQ Patent Holdings and SRQ Patent Holdings II
The Company is a party to two Amended and Restated Confirmatory Patent Assignment and Royalty Agreements, both dated November 11, 2020, with SRQ Patent Holdings and SRQ Patent Holdings II, under which the Company (or its successor) is obligated to pay to SRQ Patent Holdings or SRQ Patent Holdings II (or its designees) certain royalties on product sales or other revenue received on products that incorporate or are covered by the intellectual property that was assigned to the Company. The royalty is equal to 8% of the net sales price on product sales and, without duplication, 8% of milestone revenue or sublicense compensation. SRQ Patent Holdings and SRQ Patent Holdings II are affiliates of Mr. Jonnie Williams, Sr., a former significant stockholder. No revenue has been received subject to these agreements for the three and nine months ended September 30, 2026 and 2025.
| 33 |
MIRA Pharmaceuticals Limited License Agreement
The Company is a party to an Amended and Restated Limited License Agreement, dated June 27, 2022 and amended on April 20, 2023, with MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), under which the parties agreed to share technical information and know-how pertaining to the synthetic manufacture and formulation of the parties’ respective Supera-CBD™ and MIRA1a™ product candidates. The Company, which holds patent rights to MIRA1a™ in 22 foreign countries, was granted a perpetual, non-exclusive, royalty-free license to use improvements to MIRA1a™ made under the agreement, and MIRA was granted a limited, perpetual, worldwide, non-exclusive, royalty-free license to use Supera-CBD™ as a synthetic intermediate in the manufacture of MIRA1a™.
Series G Preferred Stock Issuance
On
May 20, 2024, the Company entered into the Series G Purchase Agreement with the Series G Investors, including PharmaCyte Biotech, Inc.
(“PharmaCyte”), pursuant to which it agreed to sell to the Series G Investors (i) an aggregate of
Series H Preferred Stock Issuance
On
September 2, 2025, the Company entered into the Series H Purchase Agreement with the Series H Investors, including PharmaCyte Biotech,
Inc., pursuant to which it agreed to sell to the Series H Investors (i) an aggregate of
On November 15, 2026, the Company entered into a Consent and Warrant Exchange Agreement with PharmaCyte. See Note 16.
Note 12 – Employee Benefit Plan
The
Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified
employees of the Company (the “401(k) Plan”). Under the 401(k) Plan, the Company matches
The
Company made matching contributions to the 401(k) Plan during the three and nine months ended September 30, 2026 of $
The
Company made matching contributions to the 401(k) Plan during the three and nine months ended September 30, 2025 of $
Note 13—Patent Assignment and Royalty Agreement
In November 2016, the Company entered into an agreement with the holders of certain intellectual property relating to the Company’s current product candidate. Under the terms of the agreement, the counterparty assigned its rights and interest in certain patents to the Company in exchange for future royalty payments based on a fixed percentage of future revenues, as defined. The agreement is effective until the later of (1) the date of expiration of the assigned patents or (2) the date of expiration of the last strategic partnership or licensing agreement including the assigned patents. No revenue has been received subject to this agreement for the three and nine months ended September 30, 2026 and 2025.
On September 2, 2025, the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) whereas, the Company agreed to acquire 100% of the membership interests of LPU Holdings LLC from the Sellers, and entered into certain other related agreements, including (i) a Support Agreement, (ii) a Registration Rights Agreement, and (iii) a License Agreement, by and between LPU and LightSolver Ltd. (the “License Agreement”, and, collectively, with the MIPA, the “Acquisition”). The Acquisition closed on September 4, 2025 (the “Acquisition Closing Date”).
The Acquisition was accounted for as an asset acquisition pursuant to ASC 805-50 as all of the fair value was concentrated in a single intangible asset, the Exclusive License.
As
consideration for the Membership Interests, the Company delivered to the Sellers
| 34 |
The
Acquisition price consisted of total upfront consideration comprised of $
Additionally,
after the closing of the Acquisition, the Company is required to pay additional contingent consideration under both the MIPA and the
License Agreement (the “Contingent Consideration”) upon the achievement of various specified milestones, including completion
of an offering of the Company’s Common Stock or Common Stock equivalents (“Equity Offering”), which Contingent Consideration
including certain specified cash payments, cash payments calculated based on any Equity Offering proceeds, shares of Common Stock that
would result in the Sellers collectively beneficially owning specified percentage of the Company and warrants to purchase Common Stock.
The Contingent Consideration was determined to be comprised of liabilities which meet the definition of a derivative under ASC 815, and
was thus required to be recognized at its fair value at closing, with such fair value included as a component of the cost of the asset
acquisition. The liability will then be remeasured each reporting period with changes in fair value recognized in earnings. As of the
Acquisition Closing Date, the Company estimated the fair value of $
The following table presents the total purchase consideration and the allocation of the purchase consideration for the Acquisition as of September 2, 2025:
Schedule of Asset Acquisition
| Acquisition Consideration (cash) | $ | |||
| Fair value of Series I Preferred Stock ( | ||||
| Transaction Costs | ||||
| Total Preliminary Consideration Transferred | ||||
| Contingent Consideration | ||||
| Purchase Price | $ |
The total purchase price was allocated in its entirety to the exclusive license under the License Agreement. The agreement has no specified term and will only be terminated upon mutual agreement between the Company and LightSolver, material breach of contract by either party, insolvency of either party, certain other failures to perform under the terms of the agreement, or at the Company’s convenience. As of the Acquisition date, the Company believes that the probability of termination under any of the above conditions is remote; the Company intends to hold the Exclusive License into perpetuity thus does not foresee a limit on the asset’s useful life as of the Acquisition Date. Management thus concludes that the Exclusive License is an indefinite-lived asset and will perform an annual assessment for impairment and will reassess whether events and circumstances indicate that the life of the asset is no longer indefinite each reporting period.
On June 26, 2026, the Company provided notice of its intention to terminate the Technology License and Development Agreement, dated as of September 2, 2025 (the “License Agreement”), by and among LightSolver, LPU Holdings LLC (“LPU”), a wholly owned subsidiary of the Company, and, solely with respect to certain provisions of the License Agreement, the Company, effective as of June 26, 2026. See Note 6 above for further information.
| 35 |
Note 14—Segments
The
Company has
To date, the Company has not generated any product revenues and has incurred losses and negative cash flows from operations since inception.
The following table presents certain financial data for the Company’s two reportable segments and a reconciliation to the Company’s consolidated net loss.
Schedule of Reconciliation Consolidated Net Loss
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Sales | ||||||||||||||||
| Pharmaceuticals | - | - | - | - | ||||||||||||
| Computing Technology | - | - | - | - | ||||||||||||
| Total Sales | - | - | - | - | ||||||||||||
| Product Cost of Sales | ||||||||||||||||
| Pharmaceuticals | - | - | - | - | ||||||||||||
| Computing Technology | - | - | - | - | ||||||||||||
| Total Cost of Sales | - | - | - | - | ||||||||||||
| Gross Profit | - | - | - | - | ||||||||||||
| Operating Expenses | ||||||||||||||||
| Administrative Expenses | ||||||||||||||||
| Pharmaceuticals | ||||||||||||||||
| Computing Technology | - | - | ||||||||||||||
| Total Administrative Expenses | ||||||||||||||||
| Research and Development Expenses | ||||||||||||||||
| Pharmaceuticals | ||||||||||||||||
| Computing Technology | - | - | ||||||||||||||
| Total Research and Development Expenses | ||||||||||||||||
| Stock Based Compensation | ||||||||||||||||
| Pharmaceuticals | - | - | - | |||||||||||||
| Computing Technology | - | - | ||||||||||||||
| Total Stock Based Compensation | - | |||||||||||||||
| Franchise Tax Expense | ||||||||||||||||
| Pharmaceuticals | ||||||||||||||||
| Computing Technology | - | - | ||||||||||||||
| Total Franchise Tax Expense | ||||||||||||||||
| Warrant Issuance Expenses | ||||||||||||||||
| Pharmaceuticals | - | - | ||||||||||||||
| Computing Technology | - | - | - | - | ||||||||||||
| Total Warrant Issuance Expenses | - | - | ||||||||||||||
| Transaction costs associated with due diligence | ||||||||||||||||
| Pharmaceuticals | - | - | - | - | ||||||||||||
| Computing Technology | - | - | ||||||||||||||
| Total Transaction costs associated with due diligence | - | - | ||||||||||||||
| Segment Net Loss | ||||||||||||||||
| Pharmaceuticals | ||||||||||||||||
| Computing Technology | - | - | ||||||||||||||
| Total Segment Net Loss | ||||||||||||||||
| Reconcilement of Net Loss | ||||||||||||||||
| Adjustments and Reconciling Items | ||||||||||||||||
| Interest and Dividend Income | ||||||||||||||||
| Pharmaceuticals | - | - | ||||||||||||||
| Computing Technology | - | - | ||||||||||||||
| Total Interest and Dividend Income | ||||||||||||||||
| Gain (Loss) on Sales of Marketable Securities | ||||||||||||||||
| Pharmaceuticals | - | - | - | |||||||||||||
| Computing Technology | - | - | ||||||||||||||
| Total Gain (Loss) on Sales of Marketable Securities | - | |||||||||||||||
| Unrealized Gain (Loss) on Marketable Securities | ||||||||||||||||
| Pharmaceuticals | - | - | ( | )- | ||||||||||||
| Computing Technology | - | ( | ) | - | ||||||||||||
| Total Unrealized Gain (Loss) on Marketable Securities | ( | ) | ( | )- | ||||||||||||
| Change in Fair Value of Derivative Liabilities | ||||||||||||||||
| Pharmaceuticals | - | ( | ) | - | ||||||||||||
| Computing Technology | - | - | ||||||||||||||
| Total Change in Fair Value of Derivative Liabilities | ( | ) | ||||||||||||||
| Impairment of Technology License | ||||||||||||||||
| Pharmaceuticals | - | - | - | - | ||||||||||||
| Computing Technology | - | - | ( | ) | - | |||||||||||
| Total Impairment of Technology License | - | - | ( | ) | - | |||||||||||
| Total Adjustments and Reconciling Items: | ||||||||||||||||
| Pharmaceuticals | - | ( | )- | - | ||||||||||||
| Computing Technology | - | ( | ) | - | ||||||||||||
| Total Adjustments and Reconciling Items | ( | )- | ( | ) | ||||||||||||
| Consolidated Net Loss: | ||||||||||||||||
| Pharmaceuticals | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Computing Technology | ( | ) | - | ( | ) | - | ||||||||||
| Consolidated Net Loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Segment assets are not reviewed by the CODM and, accordingly, asset information is not presented.
| 36 |
Note 15—Leases
Operating Leases
The Company entered into a lease for office space in June 2026 which expires in June 2028.
Future minimum lease payments included in the measurement of operating lease liabilities on the condensed consolidated balance sheet as of September 30, 2026, were as follows:
Schedule of Future Estimated Minimum Lease Payments Measurement Operating Leases Liabilities
| 2026 (Remaining) | $ | |||
| 2027 | ||||
| 2028 | ||||
| Total Minimum Lease Payments | $ | |||
| Less: effects of discounting | ( | ) | ||
| Present value of future minimum lease payments | $ | |||
| Less: current portion | ( | ) | ||
| Lease liabilities, net of current portion | $ |
Total
operating lease expense was $
Note 16—Subsequent Events
The Company has evaluated subsequent events through November 16, 2026, the date these condensed consolidated financial statements were available to be issued, and identified the following items:
Nasdaq Minimum Bid Price Deficiency Notice
On November 6, 2026, the Company received a written notice from Nasdaq stating that the Company no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Company has until May 5, 2027 to regain compliance.
Consent and Warrant Exchange Agreement
On November 15, 2026, the Company
entered into a Consent and Warrant Exchange Agreement with PharmaCyte Biotech, Inc., a related party (see Note 11). Under the
agreement, PharmaCyte agreed to exchange
Note 17–Correction of Immaterial Errors in Previously Reported Interim Financial Information
The following presents the effect of the revision described in Note 2 above on selected line items in the Company’s previously reported financial statements:
Schedule of Correction of Immaterial Errors in Previously Reported Interim Financial Information
| As previously reported in the Form 10-Q for the three months ended March 31, 2026 and June 30, 2026, respectively | Revision | As Revised | ||||||||||
| March 31, 2026 | ||||||||||||
| Stock-based Compensation | $ | $ | $ | |||||||||
| Loss from Operations | ( | ) | ( | ) | ( | ) | ||||||
| Net loss | ( | ) | ( | ) | ( | ) | ||||||
| Net Loss Attributable to Common Stockholders | ( | ) | ( | ) | ( | ) | ||||||
| Basic and Dilutive net loss per common share | ( | ) | ( | ) | ( | ) | ||||||
| Additional paid-in capital | ||||||||||||
| Accumulated deficit | ( | ) | ( | ) | ( | ) | ||||||
| June 30, 2026 | ||||||||||||
| Stock-based Compensation | $ | $ | $ | |||||||||
| Loss from Operations | ( | ) | ( | ) | ( | ) | ||||||
| Net loss | ( | ) | ( | ) | ( | ) | ||||||
| Net Loss Attributable to Common Stockholders | ( | ) | ( | ) | ( | ) | ||||||
| Basic and Dilutive net loss per common share | ( | ) | ( | ) | ( | ) | ||||||
| Additional paid-in capital | ||||||||||||
| Accumulated deficit | ( | ) | ( | ) | ( | ) | ||||||
| 37 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The information set forth below should be read in conjunction with our condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission on April 15, 2026. This discussion and analysis contains forward-looking statements based on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those indicated in these forward-looking statements as a result of certain factors, including those discussed in Part II, Item 1A of this Quarterly Report on Form 10-Q, entitled “Risk Factors.” References in this discussion and analysis to “us,” “we,” “our,” or “the Company” refer collectively to Q/C Technologies, Inc.
Our financial statements are prepared in accordance with GAAP. These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application. There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this “Form 10-Q”).
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that,” “may,” “plans,” “seeks,” “projects,” “targets,” “would” and “will” or the negative of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, but are not limited to, future financial and operating results, the company’s plans, objectives, expectations and intentions, statements concerning the Company’s expectations regarding the development of its optical processing unit initiative and related optical computing technologies and other statements that are not historical facts. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Form 10-Q and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from our historical experience and our present expectations, or projections described under the sections in this Form 10-Q and our other reports filed with the SEC titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
For a more detailed discussion of other factors that may affect our business and that could cause our actual results to differ materially from those projected in these forward-looking statements, see the risk factors and uncertainties set forth in Part II, Item 1A of this Form 10-Q and in Part I, Item 1A of our Annual Report on Form 10-K as filed with the SEC on April 15, 2026. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise, except as required by law.
Overview
QCLS is engaged in the development of a proprietary silicon photonic computing architecture for artificial intelligence (“AI”) inference. The Company focuses its efforts on its optical processing unit initiative (the “OPU Initiative”). The OPU Initiative is focused on developing next-generation optical computing technologies designed to address the performance, bandwidth, and energy limitations of traditional electronic computing architectures, including through internally developed intellectual property and strategic collaborations addressing challenges such as analog precision, nonlinear computation, and memory integration. The Company has assembled a team of experts in AI, photonics, and advanced computing to support the OPU Initiative and intends to develop proprietary optical chip architectures designed to address key bottlenecks in bandwidth, energy efficiency, and scalability for AI inference applications, while building a portfolio of foundational intellectual property through patent filings. In connection with this shift in strategic focus, the Company relocated its headquarters to San Francisco, California, where it is establishing an integrated photonics laboratory to accelerate research and development of the OPU Initiative.
| 38 |
Recent Events
Appointment of Chief Financial Officer
On August 11, 2026, the Board terminated Ian Rhodes from his role as the Company’s Interim Chief Financial Officer and appointed Todd Fagan, who had served as the Company’s Corporate Controller since March 2026, as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), in each case effective August 11, 2026. In connection with Mr. Fagan’s appointment, the Company and Mr. Fagan entered into an amendment to Mr. Fagan’s employment agreement, dated as of March 16, 2026, to reflect his new title.
Termination of Consulting Agreements and Director Resignation
On September 10, 2026, the Company and Chelsea Voss mutually terminated, effective immediately, the consulting agreement, dated as of January 16, 2026, between the Company and Ms. Voss, and the Company and Ocean Avenue Holdings LLC, an entity affiliated with Martin Shkreli, mutually terminated, effective immediately, the consulting agreement, dated as of December 8, 2025, between the Company and Ocean Avenue Holdings LLC. Also on September 10, 2026, Ms. Voss resigned as a member of the Board. Ms. Voss’s resignation was not the result of any disagreement with the operations, policies or practices of the Company.
Appointment of Chief Technology Officer
On September 14, 2026, Yossef Ehrlichman, Ph.D., who had served as the Company’s Founding Manager of Photonic Integrated Circuit Development since August 1, 2026, was appointed Chief Technology Officer of the Company. In connection with his appointment, the Company and Dr. Ehrlichman entered into a first amendment to his employment agreement, dated August 1, 2026, to change his title to Chief Technology Officer and increase his annual base salary from $260,000 to $275,000. The employment agreement also provides for a grant of restricted shares of Common Stock with a grant date fair market value of $250,000, subject to stockholder approval of an increase in the number of shares of Common Stock reserved for issuance under the Company’s long-term incentive plan, which grant would vest in three equal installments on the annual anniversaries of the grant date, subject to Dr. Ehrlichman’s continued employment.
Executive Employment Agreement
On April 13, 2026, the Company entered into an executive compensation agreement (the “Employment Agreement”) with Joshua Silverman, who serves as the Company’s Executive Chairman, setting forth the terms and conditions of Mr. Silverman’s continued employment as a member of the Company’s Board of Directors and as the Company’s Executive Chairman. The Employment Agreement has a three-year initial term commencing on April 13, 2026 (the “Effective Date”), which term automatically renews each year for successive one-year terms, unless earlier terminated by either party in accordance with the terms of the Employment Agreement.
The Employment Agreement provides that Mr. Silverman will be entitled to receive an annual base salary of one hundred and twenty thousand dollars ($120,000) (“Base Salary”), payable in accordance with the Company’s normal payroll practices. For each fiscal year during the employment period, Mr. Silverman is eligible to receive an annual bonus upon achievement of target objectives and performance criteria, payable on or before March 15 of the fiscal year following the fiscal year to which the bonus relates. The Employment Agreement also entitles Mr. Silverman to receive customary benefits and reimbursement for ordinary business expenses.
Pursuant to the Employment Agreement, Mr. Silverman is entitled to receive, on the Effective Date and subsequently on the first day of each calendar quarter thereafter, a number of fully vested restricted stock units (“RSUs”) equal to an aggregate value of $60,000 per grant calculated based on the closing price of the Company’s Common Stock as of the grant date or the closing price of the last preceding business day if the grant date is not a business day (rounded down for any fractional shares). The RSUs granted pursuant to the Employment Agreement are subject to the terms and conditions of the Company’s standard restricted stock unit award agreement and the Company’s long-term equity incentive plan. With respect to the RSU grants provided in the Employment Agreement, the Company further agreed to provide Mr. Silverman with an additional lump-sum cash payment equal to any estimated personal income and applicable employment taxes to be withheld or paid in connection with Mr. Silverman’s receipt of the applicable RSUs.
In the event Mr. Silverman’s employment is terminated by the Company for Cause (as defined in the Employment Agreement) or by Mr. Silverman without Good Reason (as defined in the Employment Agreement), Mr. Silverman will be entitled to: (i) any earned but unpaid Base Salary earned during his employment and applicable to all pay periods prior to the termination date, and (ii) any unpaid expense reimbursements and vested amounts and benefits in accordance with the terms of any applicable plan, program, corporate governance document, policy, agreement or arrangement of the Company (collectively, “Accrued Compensation”).
If Mr. Silverman’s employment is terminated prior to the end of the term by the Company without Cause or by Mr. Silverman for Good Reason, then, subject to certain conditions set forth in the Employment Agreement (including the execution and non-revocation of a general release of claims), Mr. Silverman will be entitled to: (i) Accrued Compensation; (ii) severance equal to two times the sum of (A) Mr. Silverman’s Base Salary in effect at the time his employment terminates and (B) the target bonus for the year of termination prorated based upon the number of days worked for the year of termination; and (iii) accelerated vesting of the unvested portion of any outstanding equity awards.
If Mr. Silverman’s employment is terminated prior to the end of the term by the Company without Cause or by Mr. Silverman for Good Reason within two (2) years after a Change in Control (as defined in the Employment Agreement) or within six (6) months prior to a Change in Control, Mr. Silverman will be entitled to: (i) Accrued Compensation; (ii) severance equal to three times the sum of (A) Mr. Silverman’s Base Salary in effect at the time his employment terminates and (B) the target bonus for the year of termination prorated based upon the number of days worked for the year of termination; and (iii) accelerated vesting of the unvested portion of any outstanding equity awards.
The Employment Agreement also contains customary provisions relating to, among other things, confidentiality and non-disparagement.
| 39 |
Liquidity and Capital Resources
As of September 30, 2026, the Company’s cash on hand was $2.59 million and marketable securities were $6.81 million. The Company has incurred a loss from operations of $13.72 million for the nine months ended September 30, 2026. As of September 30, 2026, the Company had working capital of $8.18 million and stockholders’ equity of $16.12 million including an accumulated deficit of $155.91 million. During the nine months ended September 30, 2026, cash flows used in operating activities were $6.64 million consisting primarily of a net loss of $11.31 million. Since its inception, the Company has met its liquidity requirements principally through the sale of its Common Stock and Preferred Stock in public and private placements.
The Company evaluated the current cash requirements for operations in conjunction with management’s strategic plan and believes that the Company’s current financial resources as of the date of the issuance of these condensed consolidated financial statements are sufficient to fund its current operating budget and contractual obligations as of September 30, 2026 as they fall due within the next twelve-month period, alleviating any substantial doubt raised by the Company’s historical operating results and satisfying its estimated liquidity needs for twelve months from the issuance of these condensed consolidated financial statements.
Financial Operations Overview
We will not generate meaningful revenue from product sales unless and until we successfully complete development and commercialization of optical computing products under our OPU Initiative. Our ability to generate revenue from our strategic focus depends on our capacity to design, fabricate and validate optical processing unit prototypes, demonstrate performance for artificial intelligence inference applications, secure any applicable regulatory and hardware certifications, and achieve commercial adoption. The development and commercialization of new photonic hardware systems require substantial time, engineering resources, and capital, and any delay or failure in these efforts would materially adversely affect our business.
Although our primary resources are now directed toward optical computing, we continue to own our historical Isomyosamine and Supera-CBD therapeutic platforms. We are evaluating strategic alternatives for these programs, including potential divestiture, partnering or licensing transactions intended to maximize their residual value.
As a result of anticipated expenditures in both our optical computing operations and our efforts to preserve and monetize our legacy pharmaceutical assets, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. If we are unable to raise additional capital on acceptable terms or at all, we may be required to delay or reduce planned development activities, defer commercialization milestones, or modify our strategic objectives.
Components of our Results of Operations
Revenue
We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products or services in the near future.
Operating Expenses
Our operating expenses are broken into several components, including research and development and general and administrative costs.
We expect operating expenses to increase as we advance development activities for our OPU Initiative.
| 40 |
Research and Development
Our research and development expenses consist of costs associated with both our optical computing business and the maintenance of our legacy pharmaceutical product candidates, Isomyosamine and Supera-CBD. For our optical computing business, these costs include personnel costs for our engineering staff, design, fabrication and testing costs for optical processing unit prototypes, consulting and general development expenses, and related engineering and technical costs. For our legacy pharmaceutical business, these costs include, but are not limited to:
| ● | Contractual agreements with third parties, including contract research organizations, for the maintenance of legacy pharmaceutical programs; | |
| ● | Outside consultants including fees and expenses; | |
| ● | Laboratory supplies and equipment; | |
| ● | Regulatory compliance; and | |
| ● | Patent application and maintenance costs to protect our intellectual property. |
Three of our six employees are involved in the research and development activities for the optical computing business. None of our other employees are principally involved in the research and development of our legacy pharmaceutical product candidates, Isomyosamine or Supera-CBD. Their salaries, wages and benefits are captured as a component of research and development but not allocated to specific projects.
We utilize third party contractors and consultants with expertise in specific research or development activities to perform work under the supervision of our researchers. We believe this allows us to control costs and to progress through the development cycle and to utilize our staff more efficiently.
It is difficult to project with absolute accuracy the duration or final cost of the development of our optical computing products or our legacy pharmaceutical product candidates, Isomyosamine and Supera-CBD, or if revenue will be generated from the commercialization of any of these products. For our optical computing business, costs will depend on the pace of prototype design and fabrication, testing and performance results, any required certifications, and commercialization timelines. For our legacy pharmaceutical business, the process of achieving regulatory approval is very costly and time consuming.
General and Administrative
General and administrative expenses primarily consist of salaries, wages and benefits for our employees in the executive, legal and accounting functions and third-party costs for legal, accounting, insurance, investor relations, stock market and board expenses.
Although treated as components of general and administrative expenses, we have chosen to disclose the following significant items separately:
Stock Based Compensation
Stock based compensation includes the fair market value, as determined using the Black-Scholes option pricing model, of stock options issued to key staff and consultants.
Other Income (Expense), net
Other income (expense), net consists of interest and dividends earned on our cash, cash equivalents, and investments, gains on the sale of marketable securities, and gains or losses on investments.
| 41 |
Results of Operations
Summary of Statements of Consolidated Operations for the Three Months Ended September 30, 2026 and 2025
The following table summarized the results of consolidated operations for the three months ended September 30, 2026 and 2025.
For the Three Months Ended September 30, | ||||||||
| Description | 2026 | 2025 | ||||||
| Operating Expenses | ||||||||
| General and Administrative | $ | 1,097,572 | $ | 967,833 | ||||
| Research and Development | 383,382 | 356,352 | ||||||
| Stock-Based Compensation | 860,667 | - | ||||||
| Franchise Tax Expenses | 123,654 | 200,050 | ||||||
| Warrant Issuance Expenses | - | 264,417 | ||||||
| Transaction costs associated with due diligence | 100,000 | - | ||||||
| Impairment of Technology License | - | - | ||||||
| Total Operating Expenses | 2,565,275 | 1,788,652 | ||||||
| Loss from Operations | (2,565,275 | ) | (1,788,652 | ) | ||||
| Other Income (Expense), net | 1,623,482 | (1,022,736 | ) | |||||
| Net Income (Loss) | $ | (941,793 | ) | $ | (2,811,388 | ) | ||
Revenue
We had no revenue from operations during the three months ended September 30, 2026 and 2025.
General and Administrative Expenses
The table below summarizes our general and administrative expenses for the three months ended September 30, 2026 and 2025:
For the Three Months Ended September 30, | ||||||||
| Description | 2026 | 2025 | ||||||
| Personnel Costs | $ | 295,129 | $ | 100,977 | ||||
| Professional Service Costs | 380,836 | 450,766 | ||||||
| Stock Market & Investor Relations Costs | 75,414 | 138,080 | ||||||
| Other Administrative Costs | 346,193 | 278,010 | ||||||
| Total General and Administrative Expenses | $ | 1,097,572 | $ | 967,833 | ||||
Personnel costs increased $194,152, or 193%, during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. During the three months ended September 30, 2025, the Company had three employees. During the three months ended September 30, 2026, there are six employees. Employment for two employees terminated in 2025 and three new employees joined the Company for the three months ended September 30, 2026. The increase in personnel cost directly relates to the increased compensation (salaries) of the new employees hired in 2026.
Professional services costs decreased $69,930, or 16%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. These costs included legal and accounting and specialized consulting services regularly incurred in the normal course of business. The decrease is primarily related to the decreases in fees for recruiting services, legal fees, and general business consulting services; primarily supporting the 2025 financial statement audit and 2025 SEC Form 10-K preparation efforts.
Stock market and investor relations costs decreased $62,666, or 45%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. These costs include the annual Nasdaq listing fees, activities related to keeping the shareholder base informed through press releases, printing materials and proxies, presentations and other communication efforts and the costs of annual stockholder meetings. The decrease is primarily due to the costs associated with a special stockholder meeting scheduled in the first half of 2025 along with the required annual stockholder meeting.
Other administrative expenses increased $68,183, or 25%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. These costs include board of director expenses, business insurance, corporate travel and other general operating expenses. Costs were generally unchanged during the three months ended September 30, 2026, compared to the three months ended September 30, 2025.
| 42 |
Stock-Based Compensation
Stock-based compensation was $860,667 for the three months ended September 30, 2026, compared to $0 for the three months ended September 30, 2025. The increase is due to several stock-based grants issued in December 2025, January 2026 and July 2026 that incurred amortization expense during the three months ended September 30, 2026.
Franchise Tax Expenses
Franchise taxes for the state of Delaware totaled $123,654 and $200,050 for the three months ended September 30, 2026 and 2025, respectively.
Warrant Issuance Expenses
Warrant issuance expenses associated with the issuance of the Series H Convertible Preferred Stock, par value $0.001 per share, and associated warrants totaled $0 and $264,417 for the three months ended September 30, 2026 and 2025, respectively. These costs included placement agent, legal and accounting fees.
Research and Development Expenses
The table below summarizes our research and development expenses for the three months ended September 30, 2026 and 2025:
For the Three Months Ended September 30, | ||||||||
| Description | 2026 | 2025 | ||||||
| Salaries and Wages | $ | 170,217 | $ | 60,000 | ||||
| Development Programs | 17,400 | 285,019 | ||||||
| Professional Services | 193,505 | 5,918 | ||||||
| Other Research and Development Expenses | 2,260 | 5,415 | ||||||
| Total Research and Development Expenses | $ | 383,382 | $ | 356,352 | ||||
Salaries and wages increased $110,217 or 184%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. During the three months ended September 30, 2025, the Company had one staff member. During the three months ended September 30, 2026, the Company increased its research and development headcount, including the hiring of Dr. Ehrlichman as Founding Manager of Photonic Integrated Circuit Development in August 2026.
Development program costs include those associated with pre-clinical development, clinical trials and other material and development programs for the three months ended September 30, 2025. Costs decreased $267,619, or 94%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. The decrease is related to the suspension of the Company’s Phase 2b study of Isomyosamine.
Professional services costs increased $187,587, or 3,170%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. These costs are primarily related to consulting services not related to a specific development program and legal and maintenance fees associated with the protection of our intellectual property.
Other research and development expenses decreased $3,155, or 58%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. These expenses include laboratory supplies, training and travel for department personnel while working with third-party trial sites. The decrease during the three months ended September 30, 2026 is directly related to the suspension of the Phase 2b study and the transition from pharmaceutical research to laser-based and optical computing.
| 43 |
Other Income and Expense
The table below summarizes our other income and expenses for the three months ended September 30, 2026 and 2025:
For the Three Months Ended September 30, | ||||||||
| Description | 2026 | 2025 | ||||||
| Interest and Dividend Income | $ | (55,477 | ) | $ | (35,955 | ) | ||
| Gain on Sale of Investments | (24,410 | ) | - | |||||
| Change in fair value of Marketable Securities | (2,595 | ) | (309 | ) | ||||
| Change in fair value of Derivative Liabilities | (1,541,000 | ) | 1,059,000 | |||||
| Total Other (Income)/Expense | $ | (1,623,482 | ) | $ | 1,022,736 | |||
Other income, net of expense totaled $1,623,482 for the three months ended September 30, 2026, and other expenses net of income, totaled $1,022,736 for the three months ended September 30, 2025.
During the three months ended September 30, 2026, compared to the three months ended September 30, 2025, interest and dividend income increased $19,522 primarily because the average investable funds balance in the third quarter of 2025 was significantly lower than the balance in the third quarter of 2026.
During the three months ended September 30, 2026, we recorded a gain of $1,541,000 related to the change in fair value of the Series H Derivative liabilities, which is recorded in other income on the Statements of Operations. We estimated the $25,000 fair value of the bifurcated embedded derivative at September 30, 2026 using a Monte Carlo simulation model, with the following inputs: the fair value of our common stock of $0.85 on the valuation date, estimated equity volatility of 105.0%, the time to maturity of 0.42 years, a discounted market interest rate of 4.2%, dividend rate of 7.0%, a penalty dividend rate of 15.0%, and probability of default of 4.4%.
During the three months ended September 30, 2025, we recorded a loss of $1,059,000 related to the change in fair value of the Series H Derivative liabilities, which is recorded in other income (expense) on the Statements of Operations. We estimated the $2,896,000 fair value of the bifurcated embedded derivative at September 30, 2025 using a Monte Carlo simulation model, with the following inputs: the fair value of our common stock of $1.62 on the valuation date, estimated equity volatility of 100.0%, estimated traded volume volatility of 275.0%, the time to maturity of 1 year, a discounted market interest rate of 4.18%, dividend rate of 10.0%, a penalty dividend rate of 15.0%, and probability of default of 5.2%.
Summary of Statements of Consolidated Operations for the Nine Months Ended September 30, 2026 and 2025
The following table summarized the results of consolidated operations for the nine months ended September 30, 2026 and 2025.
| For the Nine Months Ended September 30, | ||||||||
| Description | 2026 | 2025 | ||||||
| Operating Expenses | ||||||||
| General and Administrative | $ | 3,630,013 | $ | 2,703,815 | ||||
| Research and Development | 1,130,049 | 2,775,337 | ||||||
| Stock-Based Compensation | 5,343,060 | 189,490 | ||||||
| Franchise Tax Expenses | 343,057 | 200,050 | ||||||
| Warrant Issuance Expenses | - | 264,417 | ||||||
| Transaction costs associated with due diligence | 100,000 | - | ||||||
| Impairment of Technology License | 3,177,999 | - | ||||||
| Total Operating Expenses | 13,724,178 | 6,133,109 | ||||||
| Loss from Operations | (13,724,178 | ) | (6,133,109 | ) | ||||
| Other Income, net | 2,410,398 | 400,783 | ||||||
| Net Loss | $ | (11,313,780 | ) | $ | (5,732,326 | ) | ||
| 44 |
Revenue
We had no revenue from operations during the nine months ended September 30, 2026 and 2025.
General and Administrative Expenses
The table below summarizes our general and administrative expenses for the nine months ended September 30, 2026 and 2025:
For the Nine Months Ended September 30, | ||||||||
| Description | 2026 | 2025 | ||||||
| Personnel Costs | $ | 573,129 | $ | 322,087 | ||||
| Professional Service Costs | 1,467,231 | 972,933 | ||||||
| Stock Market & Investor Relations Costs | 220,842 | 544,102 | ||||||
| Other Administrative Costs | 1,368,811 | 864,693 | ||||||
| Total General and Administrative Expenses | $ | 3,630,013 | $ | 2,703,815 | ||||
Personnel costs increased $251,042, or 78%, during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. During the nine months ended September 30, 2025, the Company had three employees, during the nine months ended September 30, 2026, there are three employees. Employment for two employees terminated in 2025 and two new employees joined the Company for the nine months ended September 30, 2026. The increase in personal cost directly relates to the increased compensation (salaries) of the new employees hired in 2026.
Professional services costs increased $494,298, or 51%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. These costs included legal and accounting and specialized consulting services regularly incurred in the normal course of business. The increase is primarily related to increases in fees for recruiting services, legal fees, and general business consulting services; primarily supporting the 2025 financial statement audit and 2025 SEC Form 10-K preparation efforts.
Stock market and investor relations costs decreased $323,260, or 59%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. These costs include the annual Nasdaq listing fees, activities related to keeping the shareholder base informed through press releases, printing materials and proxies, presentations and other communication efforts and the costs of annual stockholder meetings. The decrease is primarily due to the costs associated with a special stockholder meeting scheduled in the first half of 2025 along with the required annual stockholder meeting.
Other administrative expenses increased $504,118 or 38%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. These costs include board of director expenses, business insurance, corporate travel and other general operating expenses. Costs were generally unchanged during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025.
Stock-Based Compensation
Stock-based compensation increased $5,616,412, or 2,055%, during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The increase is primarily a result of restricted stock units and options issued to Chelsea Voss during the first quarter, stock options issued to the Board of Directors during the second quarter, restricted stock awards, warrants issued to consultants, stock options, and the acceleration of the stock-based compensation expense for Chelsea Voss and Ocean Avenue Holdings during the third quarter of 2026.
Franchise Tax Expenses
Franchise taxes for the state of Delaware totaled $343,057 and $200,050 for the nine months ended September 30, 2026 and 2025, respectively. The increase is because the Franchise tax for 2025 was paid late and is reflected in the condensed consolidated financial statements as of September 30, 2026 as well as a quarterly tax payment which did not occur in 2025.
Impairment of Technology License
During the nine months ended September 30, 2026, impairment of technology license increased by $3,177,999 related to the termination of the LightSolver agreement.
| 45 |
Warrant Issuance Expenses
Warrant issuance expenses associated with the issuance of the Series H Convertible Preferred Stock, par value $0.001 per share, and associated warrants totaled $0 and $264,417 for the nine months ended September 30, 2026 and 2025, respectively. These costs included placement agent, legal and accounting fees.
Research and Development Expenses
The table below summarizes our research and development expenses for the nine months ended September 30, 2026 and 2025:
For the Nine Months Ended September 30, | ||||||||
| Description | 2026 | 2025 | ||||||
| Salaries and Wages | $ | 314,805 | $ | 183,362 | ||||
| Development Programs | 541,451 | 2,326,514 | ||||||
| Professional Services | 271,533 | 234,927 | ||||||
| Other Research and Development Expenses | 2,260 | 30,534 | ||||||
| Total Research and Development Expenses | $ | 1,130,049 | $ | 2,775,337 | ||||
Salaries and wages increased $131,443, or 72%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. During the nine months ended September 30, 2025, the Company had one staff member. During the nine months ended September 30, 2026, the Company began to build out R&D staffing for the computing technology business.
Development program costs include those associated with pre-clinical development, clinical trials and other material and development programs. Costs decreased $1,785,063, or 77%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. The decrease is related to the suspension of the Company’s Phase 2b study of Isomyosamine.
Professional services costs increased $36,606, or 16%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. These costs are primarily related to consulting services not related to a specific development program and legal and maintenance fees associated with the protection of our intellectual property.
Other research and development expenses decreased $28,274, or 93%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. The 2025 expenses would normally include laboratory supplies, training and travel for department personnel while working with third-party trial sites. The decrease during the nine months ended September 30, 2026 is primarily due to no spending in 2026 related to the pharmaceutical business.
Other Income and Expense
The table below summarizes our other income and expenses for the nine months ended September 30, 2026 and 2025:
For the Nine Months Ended September 30, | ||||||||
| Description | 2026 | 2025 | ||||||
| Interest and Dividend Income | $ | (227,442 | ) | $ | (156,042 | ) | ||
| (Gain)/Loss on Investments | (55,651 | ) | (2,176 | ) | ||||
| Loss on changes in fair value of Equity Investments | 4,695 | 1,435 | ||||||
| (Gain)/Loss on changes in fair value of Derivative Liabilities | (2,132,000 | ) | (244,000 | ) | ||||
| Total Other Income | $ | (2,410,398 | ) | $ | (400,783 | ) | ||
Other income, net of expenses totaled $2,410,398, for the nine months ended September 30, 2026, and other income, net of expenses, totaled $400,783 for the nine months ended September 30, 2025.
During the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025, interest and dividend income increased $71,400 primarily because the average investable funds balance for the nine months ended September 30, 2025 was significantly lower than the balance for the nine months ended September 30, 2026.
During the nine months ended September 30, 2026, we recorded a gain of $2,132,000 related to the change in fair value of the Series H Derivative liabilities, which is recorded in other income on the Statements of Operations. We estimated the $25,000 fair value of the bifurcated embedded derivative at September 30, 2026 using a Monte Carlo simulation model, with the following inputs: the fair value of our common stock of $0.85 on the valuation date, estimated equity volatility of 105.0%, the time to maturity of 0.42 years, a discounted market interest rate of 4.2%, dividend rate of 7.0%, a penalty dividend rate of 15.0%, and probability of default of 4.4%.
During the nine months ended September 30, 2025, we recorded a gain of $244,000 related to the change in fair value of the derivative liabilities as follows:
| ● | For the Series F-1 Derivative (as defined herein), we recorded a gain of $1,303,000. We estimated the $0 fair value of the bifurcated embedded derivative at September 30, 2025 using a Monte Carlo simulation model, with the following inputs: the fair value of our Common Stock of $0.12 on the valuation date, estimated equity volatility of 125.0%, estimated traded volume volatility of 345.0%, the time to maturity of 0.5 year, a discounted market interest rate of 4.28%, dividend rate of 10.0%, a penalty dividend rate of 15.0%, and probability of default of 4.4%. | |
| ● | For the Series H Derivative (as defined herein), we recorded a loss of $1,059,000. We estimated the $2,896,000 fair value of the bifurcated embedded derivative at September 30, 2025 using a Monte Carlo simulation model, with the following inputs: the fair value of our common stock of $1.62 on the valuation date, estimated equity volatility of 100.0%, estimated traded volume volatility of 275.0%, the time to maturity of 1 year, a discounted market interest rate of 4.18%, dividend rate of 10.0%, a penalty dividend rate of 15.0%, and probability of default of 5.2%. |
| 46 |
Liquidity and Capital Resources
Overview
Our primary source of liquidity to date has been funding from our stockholders through the sale of equity securities and the exercise of derivative securities, including warrants. We expect our primary sources of future liquidity in the short to mid-term to be derived from the exercise of outstanding warrants, and future equity or debt financings. However, as of September 30, 2026, the exercise prices of our outstanding warrants exceeded the closing price of our Common Stock of $0.85 per share, and there can be no assurance that any outstanding warrants will be exercised.
As of September 30, 2026, the Company’s cash on hand was $2,585,051 and marketable securities were $6,805,270. The Company has incurred a net loss attributable to common stockholders of $11,786,978 for the nine months ended September 30, 2026. As of September 30, 2026, the Company had working capital of $8,182,050 and stockholders’ equity of $16,123,989, including an accumulated deficit of $155,909,713. Since its inception, the Company has met its liquidity requirements principally through the sale of its Common Stock and preferred stock in public and private placements.
Based on our current operating plan, existing cash balances, and expected cash flows, management believes that the Company has sufficient liquidity to fund its operations for at least the next twelve months. However, our ability to continue as a going concern, fund our operations beyond that period, and to pursue our growth strategy, is dependent on our ability to manage operating expenses and access additional capital as needed. Liquidity constraints and access to capital markets could negatively affect our liquidity and require changes to our operating or investment strategy.
Our future capital requirements will depend on numerous factors, including the timing and extent of market acceptance of our products and services, investments in product development, sales and marketing activities, working capital requirements, and the timing and amount of future revenue. We may seek to raise additional capital through equity or debt financings, strategic partnerships, or other arrangements. There can be no assurance that such financing will be available on acceptable terms, or at all.
Operating Activities
During the nine months ended September 30, 2026, cash flows used in operating activities were $6,640,396, consisting primarily of a net loss of $11,313,780 and changes in operating assets and liabilities.
During the nine months ended September 30, 2025, cash flows used in operating activities were $5,865,877, consisting primarily of a net loss of $5,732,326, and a gain on the fair value of derivatives of $244,000, offset by an increase in prepaid expenses of $256,561, an increase in trade and other payables of $178,261, and an increase in share-based compensation of $189,490.
Investing Activities
Our net cash provided by investing activities totaled $7,883,412 for the nine months ended September 30, 2026. During the nine months ended September 30, 2026, we purchased securities totaling $305,806 and sold securities totaling $8,352,530. We also purchased equipment for $163,312.
Our net cash provided by investing activities totaled $3,245,029 for the nine months ended September 30, 2025. During the nine months ended September 30, 2025, we purchased the LightSolver license totaling $2,009,022, securities totaling $5,955,495 and sold securities totaling $11,209,546.
Financing Activities
Net cash provided by financing activities during the nine months ended September 30, 2026 was $355,039 which consisted of dividends paid on preferred stock offset by receipts for the exercise of outstanding warrants.
Net cash provided by financing activities during the nine months ended September 30, 2025 was $9,351,879 which consisted of receipts for the exercise of outstanding warrants and the proceeds from the sale of the Series H Preferred Stock.
| 47 |
February 2023 Offering
In February 2023, the Company issued shares of its Series F Convertible Preferred Stock and warrants to purchase shares of Common Stock (the “Series F Warrants”) in a private placement (collectively, the “February 2023 Offering”). All shares of Series F Convertible Preferred Stock issued in the February 2023 Offering have been converted and none remain outstanding. As of September 30, 2026, Series F Warrants to purchase up to 3,139,325 shares of Common Stock were outstanding at an exercise price of $3.3713 per share (the “Series F Exercise Price”), which warrants expire on August 15, 2030. See Note 8 to the condensed consolidated financial statements included in this Form 10-Q for additional information.
Series F-1 Private Placement
On May 20, 2024, the Company entered into a Securities Purchase Agreement (the “Series F-1 Purchase Agreement”) with certain accredited investors (the “Series F-1 Investors”) pursuant to which it agreed to sell to the Series F-1 Investors (i) shares of the Company’s newly-designated Series F-1 Preferred Stock, (ii) short-term warrants to acquire up to an aggregate of 27,813 shares of Common Stock (the “Series F-1 Short-Term Warrants”) at an exercise price of $181.60 per share (the “Series F-1 Short-Term Warrants Exercise Price”), and (iii) long-term warrants to acquire up to an aggregate of 27,813 shares of Common Stock (the “Series F-1 Long-Term Warrants,” and collectively with the Series F-1 Short-Term Warrants, the “Series F-1 Warrants”) at an initial exercise price of $181.60 (the “Series F-1 Long-Term Exercise Price” and, together with the Series F-1 Short-Term Warrants Exercise Price, the “Series F-1 Exercise Price”) per share (collectively, the “Series F-1 Private Placement”). The closing of the Series F-1 Private Placement occurred on May 23, 2024 (the “Series F-1 Closing Date”).
Pursuant to that certain Omnibus Amendment Agreement, dated as of April 8, 2025, by and among the Company and the Required Holders (as defined in the Series F-1 Warrants) (the “April 2025 Amendment Agreement”), the Series F-1 Short-Term Warrants were extended to expire five years from the date of issuance, the Series F-1 Short-Term Warrants were extended to expire five years from the date of issuance.
The exercise price of the Series F-1 Warrants and the number of shares issuable upon exercise of the Series F-1 Warrants are subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment, on a “full ratchet” basis, in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable exercise price (subject to certain exceptions). Upon any such price-based adjustment to the exercise price, the number of shares issuable upon exercise of the Series F-1 Warrants will be increased proportionately.
| 48 |
On April 17, 2025, in connection with the issuance of stock options to certain officers of the Company and pursuant to the full ratchet anti-dilution provisions contained in the Series F-1 Warrants, the Series F-1 Exercise Price was adjusted to $18.32 per share. In September 2025, in connection with the 2025 Reverse Stock Split, and pursuant to the stock combination event adjustment provisions contained in the Series F-1 Warrants, the Series F-1 Exercise Price was reduced to $3.3713 per share and the number of shares of Common Stock issuable upon exercise of the Series F-1 Warrants was adjusted proportionally.
As of September 30, 2026, the Series F-1 Exercise Price was equal to $3.3713 per share and Series F-1 Short-Term Warrants and Series F-1 Long-Term Warrants were outstanding to purchase up to 1,322,942 shares and 1,497,942 shares of Common Stock, respectively.
Series G Private Placement
On May 20, 2024, the Company entered into a Securities Purchase Agreement (the “Series G Purchase Agreement” and collectively with the Series F-1 Purchase Agreement, each a “Purchase Agreement” and collectively, the “Purchase Agreements”) with certain accredited investors (the “Series G Investors” and collectively with the Series F-1 Investors, the “Investors”), pursuant to which it agreed to sell to the Series G Investors (i) an aggregate of 8,950 shares of the Company’s newly-designated Series G Preferred Stock, initially convertible into up to 49,288 shares of the Company’s Common Stock at an initial conversion price of $181.60 per share (the “Series G Conversion Price”), (ii) short-term warrants to acquire up to an aggregate of 49,288 shares of Common Stock (the “Series G Short-Term Warrants”) at an exercise price of $181.60 per share, and (iii) long-term warrants to acquire up to an aggregate of 49,288 shares of Common Stock (the “Series G Long-Term Warrants,” and collectively with the Series G Short-Term Warrants, the “Series G Warrants”) at an initial exercise price of $181.60 per share (the “Series G Exercise Price”) (collectively, the “Series G Private Placement” and collectively with the Series F-1 Private Placement, each a “Private Placement” and collectively, the “Private Placements”). The closing of the Series G Private Placement occurred on May 23, 2024 (the “Series G Closing Date” and collectively with the Series F-1 Closing Date, the “Closing Date”).
On April 17, 2025, in connection with the issuance of stock options to certain officers of the Company, the Series G Conversion Price was equal to $18.32 per share due to the full ratchet anti-dilution provisions contained in the Series G Certificate of Designations. In August 2025, in connection with the 2025 Reverse Stock Split, and pursuant to the stock combination event adjustment provisions contained in the Series G Certificate of Designations, the Series G Conversion Price was reduced to $3.3713 per share.
We received net proceeds from the Series G Private Placement of approximately $8.9 million, after deducting various fees and expenses. We intend to use the net proceeds from this offering for general corporate purposes.
As of September 30, 2026, there were 8,812 shares of Series G Preferred Stock outstanding, Series G Short-Term Warrants were fully expired, and Series G Long-Term Warrants were outstanding to purchase up to 2,135,667 shares of Common Stock.
Series G Warrants
Pursuant to the Series G Private Placement, the Company issued to investors (i) the Series G Long-Term Warrants to purchase 49,288 shares of Common Stock, with an initial exercise price of $181.60 per share (subject to adjustment, the “Series G Exercise Price”), for a period of five years from the date of issuance and (ii) the Series G Short-Term Warrants to purchase 49,288 shares of Common Stock, with an initial exercise price of $181.60 per share (subject to adjustment), for a period of eighteen months from the date of issuance. On April 17, 2025, in connection with the issuance of stock options to certain officers of the Company and pursuant to the full ratchet anti-dilution provisions contained in the Series G Warrants, the Series G Exercise Price was equal to $18.32 per share and the number of shares of Common Stock issuable upon exercise of the Series G Warrants was adjusted proportionally. In August 2025, in connection with the 2025 Reverse Stock Split and pursuant to the stock combination event adjustment provisions contained in the Series G Warrants, the Series G Exercise Price was reduced to $3.3713 per share and the number of shares of Common Stock issuable upon exercise of the Series G Warrants was adjusted proportionally.
The exercise price of the Series G Warrants and the number of shares issuable upon exercise of the Series G Warrants are subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment, on a “full ratchet” basis, in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable exercise price (subject to certain exceptions). Upon any such price-based adjustment to the exercise price, the number of shares issuable upon exercise of the Series G Warrants will be increased proportionately.
| 49 |
Placement Agent Warrants
In connection with the Private Placements, pursuant to (A) an engagement letter (the “GPN Agreement”) with GP Nurmenkari Inc. (“GPN”) and (B) an engagement letter (the “Palladium Agreement,” and collectively with the GPN Agreement, the “Engagement Letters”) with Palladium Capital Group, LLC (“Palladium,” and collectively with GPN, the “Placement Agents”), the Company engaged the Placement Agents to act as non-exclusive placement agents in connection with each Private Placement, pursuant to which, the Company agreed to (i) pay the Placement Agents a cash fee equal to 3% of the gross proceeds of each Private Placement (including any cash proceeds realized by the Company from the exercise of the Series F Warrants), (ii) reimbursement and payment of certain expenses, and (iii) issue to the Placement Agents on the Closing Date, warrants to purchase up to an aggregate of 693,833 of shares of Common Stock to each Placement Agent, which is equal to 3% of the aggregate number of shares of Common Stock underlying the securities issued in each Private Placement, including upon exercise of any Series F Warrants, with terms identical to the Series G Long-Term Warrants and Series F-1 Long-Term Warrants.
Series H Preferred Stock
On September 2, 2025, we entered into the Securities Purchase Agreement (the “Series H Purchase Agreement”) with certain accredited investors (the “Series H Investors”), pursuant to which we issued and sold on September 4, 2025 (the “Series H Closing Date”) in a private placement (i) an aggregate of 7,000 shares of Series H Preferred Stock, initially convertible into up to 1,400,000 shares of the Company’s Common Stock (the “Series H Conversion Shares”) at an initial conversion price of $5.00 per share (the “Series H Conversion Price”) and (ii) warrants to acquire up to an aggregate of 1,400,000 shares of Common Stock at an initial exercise price of $5.00 per share (the “Series H Investor Warrants”) (collectively, the “Series H Private Placement”).
The terms of the shares of Series H Preferred Stock are as set forth in the Certificate of Designations of the Series H Convertible Preferred Stock (the “Series H Certificate of Designations”), which was filed and became effective with the Secretary of State of the State of Delaware on September 3, 2025. The Series H Investor Warrants became exercisable upon receipt of the Series H Stockholder Approval (as defined herein) and expire five years from the date of the Series H Stockholder Approval.
In connection with the Series H Private Placement, pursuant to an engagement agreement (the “GPN Engagement Agreement”), dated August 28, 2025, between the Company and GP Nurmenkari Inc. (“GPN”), the Company engaged GPN to act as a non-exclusive placement agent in connection with the Series H Private Placement. Pursuant to the GPN Engagement Agreement, the Company agreed to (i) pay GPN a cash fee equal to 4% of the gross proceeds of the Series H Private Placement (including any cash proceeds realized by the Company from the exercise of outstanding warrants of the Company), (ii) reimbursement and payment of certain expenses, and (iii) issue to GPN on the Series H Closing Date, warrants to purchase up to an aggregate number of shares of Common Stock equal to 4% of the aggregate number of shares of Common Stock underlying the securities issued in the Series H Private Placement, with terms identical to the Series H Investor Warrants.
Additionally, pursuant to an engagement agreement (the “Rodman Engagement Agreement” and, collectively with the GPN Engagement Agreement, the “Engagement Agreements”), dated August 27, 2025, between the Company and Rodman & Renshaw LLC (“Rodman”), the Company engaged Rodman and H.C. Wainwright & Co., LLC (“Wainwright” and, together with Rodman and GPN, the “Placement Agents”) to act as non-exclusive placement agents in connection with the Series H Private Placement. Pursuant to the Rodman Engagement Agreement, the Company agreed to (i) pay Rodman and Wainwright an aggregate cash fee equal to 5% of the gross proceeds of the Series H Private Placement (including any cash proceeds realized by the Company from the exercise of outstanding warrants of the Company) (provided, however, that such cash fee shall be reduced to 2.5% with respect to any gross proceeds raised from the enumerated list of existing investors of the Company (the “Existing Series H Investors”)), (ii) reimburse and pay certain expenses, and (iii) issue to Rodman and Wainwright on the Series H Closing Date, warrants to purchase up to an aggregate number of shares of Common Stock equal to 5% (or 2.5% in case of securities issued to Existing Series H Investors) of the aggregate number of shares of Common Stock underlying the securities issued in the Series H Private Placement, with terms identical to the Series H Investor Warrants.
The Series H Private Placement was exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. Each of the Series H Investors in the Series H Private Placement has represented to us that it is an accredited investor within the meaning of Rule 501(a) of Regulation D and that it is acquiring the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The shares of Series H Preferred Stock and Series H Investor Warrants were offered without any general solicitation by us or our representatives.
| 50 |
Shares of Series H Preferred Stock
All shares of capital stock of the Company rank junior to the shares of Series H Preferred Stock, with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company. Further to the foregoing, shares of Series H Preferred Stock rank junior to shares of (i) Series F Convertible Preferred Stock, par value $0.001 per share, of the Company issued and outstanding pursuant to the Series F Certificate of Designations, (ii) Series F-1 Convertible Preferred Stock, par value $0.001 per share, of the Company issued and outstanding pursuant to the Series F-1 Certificate of Designations, and (iii) Series G Convertible Preferred Stock, par value $0.001 per share, of the Company issued and outstanding pursuant to the Series G Certificate of Designations, in each case, with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company.
Following the receipt of the Series H Stockholder Approval (as defined herein), the shares of Series H Preferred Stock became convertible into Common Stock at the election of the holder at any time at the initial Series H Conversion Price of $5.00. The Series H Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications, stock combinations and the like. The Series H Conversion Price may also be voluntarily reduced by the Company to any amount and for any period of time deemed appropriate by the Board at any time with the prior written consent of the holders of at least a majority of the outstanding shares of Series H Preferred Stock, subject to the rules and regulations of Nasdaq.
The holders of the shares of Series H Preferred Stock are entitled to dividends of 7% per annum, compounded each calendar quarter, which are payable in arrears (i) on the first trading day of each quarter, commencing on October 1, 2025 and (ii) upon any redemption or any required payment upon any Triggering Event (as defined in the Series H Certificate of Designations). The holders of the shares of Series H Preferred Stock are also entitled to receive a dividend make-whole payment.
Upon the occurrence and during the continuance of a Triggering Event, the shares of Series H Preferred Stock accrue dividends at the rate of 15% per annum. The holders of the shares of Series H Preferred Stock are entitled to vote with holders of the Common Stock on an as-converted basis, with the number of votes to which each holder of shares of Series H Preferred Stock is entitled to be calculated assuming a conversion price of $4.83 per share, which was the Minimum Price (as defined in Rule 5635 of the Rules of the Nasdaq Stock Market) applicable immediately before the execution and delivery of the Series H Purchase Agreement, subject to certain beneficial ownership limitations as set forth in the Series H Certificate of Designations.
The Series H Certificate of Designations includes certain Triggering Events (as defined in the Series H Certificate of Designations), including, among other things, the suspension from trading or the failure of our Common Stock to be trading or listed (as applicable) on an eligible market for a period of five (5) consecutive trading days and our failure to pay any amounts due to the holders of the shares of Series H Preferred Stock when due. Upon the occurrence of a Triggering Event, each holder of shares of Series H Preferred Stock will be able to require us to redeem in cash any or all of the holder’s shares of Series H Preferred Stock at a premium set forth in the Series H Certificate of Designations. Further, upon a Triggering Event, a holder of shares of Series H Preferred Stock, at such holder’s option, by delivery of a notice of conversion (“Triggering Event Conversion Notice”) to the Company, may convert all, or any number of shares of Series H Preferred Stock held by such holder into shares of Common Stock at a price equal to the lowest of (A) the applicable Series H Conversion Price as in effect on the applicable date of conversion, and (B) $0.616, which was 20% of the “Minimum Price” (as defined in Nasdaq Stock Market Rule 5635) on the date on which the Series H Stockholder Approval (as defined herein) was obtained or, in any case, such lower amount as permitted, from time to time, by the Nasdaq Capital Market, and, in each case, subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events, which are subject to certain adjustments as set forth in the Series H Certificate of Designations (the “Floor Price”), and (ii) 80% of the lowest volume weighted average price of the Common Stock of any trading day during the twenty (20) consecutive trading day period ending and including the trading day immediately preceding the delivery or deemed delivery of the applicable Triggering Event Conversion Notice.
Notwithstanding the foregoing, our ability to issue any shares of Common Stock upon conversion of any shares of Series H Preferred Stock or otherwise pursuant to the terms of the Series H Certificate of Designations is subject to certain limitations set forth in the Series H Certificate of Designations, including a limit on the number of shares that may be issued until the time, if any, that our stockholders have approved the issuance of the Series H Conversion Shares and shares issuable upon exercise of the Series H Investor Warrants (the “Series H Stockholder Approval”). The Series H Stockholder Approval was obtained on November 14, 2025 at a special meeting of stockholders of the Company. Further, the Series H Certificate of Designations contains a certain beneficial ownership limitation which applies to each holder of the shares of Series H Preferred Stock, other than PharmaCyte Biotech, Inc. (“PharmaCyte”), after giving effect to the issuance of shares of Common Stock issuable upon conversion of the shares of Series H Preferred Stock.
| 51 |
Warrants
The Series H Investor Warrants were exercisable upon receipt of Series H Stockholder Approval, at an exercise price of $5.00 per share, and expire five years from the date of the Series H Stockholder Approval. The exercise price of each Series H Investor Warrant is subject to customary adjustments for stock dividends, stock splits, reclassifications, stock combinations and the like. Upon any such price-based adjustment to the exercise price, the number of shares of Common Stock issuable upon exercise of the Series H Investor Warrants will be increased proportionately. The exercise price may also be voluntarily reduced by the Company to any amount and for any period of time with the prior written consent of the holders of at least a majority of the outstanding Series H Investor Warrants, subject to the rules and regulations of Nasdaq. The Series H Investor Warrants may be exercised for cash, provided that, if there is no effective registration statement available registering the exercise of the Series H Investor Warrants, the Series H Investor Warrants may be exercised on a cashless basis.
MIPA
On September 2, 2025, the Company entered into a Membership Interest Purchase Agreement (the “MIPA”), by and among the Company, LPU and the members of LPU identified on the signature pages attached thereto (the “Sellers”), pursuant to which the Company agreed to acquire 100% of the membership interests (the “Membership Interests”) of LPU from the Sellers (the “Acquisition”).
As consideration for the Membership Interests, the Company delivered to the Sellers that number of shares of Series I Preferred Stock that is convertible into a number of shares of Common Stock equal to 747,362, subject to certain conversion limitations as described in the Certificate of Designations for the Series I Convertible Preferred Stock. As of September 30, 2026, no shares of Series I Preferred Stock are issued and outstanding.
Following the closing of the Acquisition, the Sellers are entitled to additional contingent consideration (the “Contingent Consideration”) upon the achievement of various specified milestones, including completion of an offering of the Company’s Common Stock or Common Stock equivalents (an “Equity Offering”), which Contingent Consideration includes certain specified cash payments, cash payments calculated based on any Equity Offering proceeds, shares of Common Stock that would result in the Sellers collectively beneficially owning a specified percentage of the Company, and warrants to purchase Common Stock (collectively, the “Milestone Securities”).
Notwithstanding the foregoing, the Company’s ability to issue the Milestone Securities or the Common Stock underlying the Milestone Securities is subject to certain limitations, including a limit on the number of shares that may be issued until the time, if any, that the Company’s stockholders have approved the issuance in accordance with Nasdaq listing standards (the “MIPA Stockholder Approval”). The MIPA Stockholder Approval was obtained on November 14, 2025, at a special meeting of stockholders of the Company.
In connection with the transaction contemplated by the MIPA, the Company engaged Palladium to act as a non-exclusive financial advisor pursuant to the Advisory Agreement. Pursuant to the Advisory Agreement, the Company agreed to (i) pay Palladium a monthly retainer of $15,000 and (ii) issue to Palladium 15,433 shares of Common Stock of the Company, which shares were issued following the date of the receipt of the MIPA Stockholder Approval.
License Agreement
In connection to the transactions contemplated by the MIPA, prior to entering into the MIPA, on September 2, 2025, LPU and LightSolver Ltd., an Israeli company (“LightSolver” or “Licensor”) entered into a license agreement (as may be subsequently amended, supplemented, amended and restated or otherwise modified, the “License Agreement”). Pursuant to the License Agreement, LightSolver granted LPU, among other things, an exclusive license to use and commercialize its proprietary laser processing hardware units (the “Machines”) specifically configured for cryptocurrency mining applications and its proprietary intangible technology necessary or useful to utilize the Machines (the “Technology”) solely for cryptocurrency mining applications.
In addition, pursuant to the License Agreement, LightSolver agreed to perform certain development work to develop, customize, configure, and enhance its proprietary Machines and Technology for cryptocurrency mining applications, for which LPU will pay LightSolver, upon the achievement of certain associated developmental milestones by LightSolver, (the “Milestone Events”), a total of up to $8,500,000 in non-recurring engineering fees. In addition to such non-recurring engineering fees, no later than one (1) business day after the effective date of the License Agreement, LPU agreed to make a one-time cash payment to LightSolver equal to the greater of (i) 25% of the aggregate proceeds received by the Company from the Private Placement and (ii) $1,500,000. Furthermore, promptly upon the occurrence of any of the Milestone Events, LPU agreed to deliver, or cause to be delivered, to LightSolver the consideration described above.
On June 26, 2026, the Company provided notice of its intention to terminate the License Agreement, effective as of June 26, 2026. In connection with such termination, LPU was automatically and immediately relieved from its obligation to make any additional Milestone Event payments or other payments described above, and LightSolver has no right to receive any further contingent consideration under the License Agreement or the MIPA.
| 52 |
Critical Accounting Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment. Actual results inevitably will differ from those estimates, and such differences may be material to the financial statements. The most significant accounting estimates inherent in the preparation of our financial statements include estimates associated with the determinations of the fair-market value of the preferred stock, stock-based compensation, and the impairment analysis of intangibles.
Our financial position, results of operations and cash flows are impacted by the accounting policies we have adopted. In order to get a full understanding of our financial statements, one must have a clear understanding of the accounting policies employed. A summary of our critical accounting policies is presented within the notes to our consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Our management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may materially differ from these estimates under different assumptions or conditions.
Our critical accounting estimates have not changed materially from those previously reported in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on April 15, 2026.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”) Rule 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during our last fiscal quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 53 |
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
From time to time we are a party to litigation and subject to claims incident to the ordinary course of business. Future litigation may be necessary to defend ourselves and our customers by determining the scope, enforceability, and validity of third-party proprietary rights or to establish our proprietary rights. For a description of certain legal proceedings, please read Note 9 to the interim condensed consolidated financial statements, which information is incorporated herein by reference.
Item 1A. Risk Factors
Except as set forth below, there have been no material changes to the risk factors previously disclosed in “Item 1A. Risk Factors” of our annual report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on April 15, 2026. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in our annual report and below, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results, and stock price.
If we fail to maintain compliance with Nasdaq’s minimum bid price requirement or other continued listing requirements, our Common Stock could be delisted, which could trigger redemption and other rights under our outstanding preferred stock and adversely affect the liquidity and price of our Common Stock.
Our Common Stock is listed on The Nasdaq Capital Market. To maintain our listing, we must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum closing bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and minimum stockholders’ equity of $2.5 million. On September 30, 2026, the closing price of our Common Stock was $0.85 per share. If the closing bid price of our Common Stock remains below $1.00 per share for 30 consecutive business days, we expect to receive a deficiency notice from Nasdaq. On November 6, 2026, we received a written notice from the Listing Qualifications Department of Nasdaq indicating that we were not in compliance with the minimum bid price requirement, and we have been provided a compliance period until May 5, 2027 to regain compliance. We previously received a deficiency notice relating to the minimum bid price requirement in March 2025 and regained compliance in September 2025 following the 2025 Reverse Stock Split. To regain or maintain compliance, we may be required to effect an additional reverse stock split, which would require stockholder approval and may not result in a sustained increase in the price of our Common Stock. In addition, Nasdaq’s rules limit the availability of compliance periods for companies that have effected reverse stock splits within specified look-back periods, and, as a result, we may not be afforded a compliance period, or may have a shorter period, to regain compliance with the minimum bid price requirement. There can be no assurance that we will be able to regain or maintain compliance with Nasdaq’s continued listing requirements.
In addition, under the certificates of designations governing our Series G Preferred Stock and Series H Preferred Stock, the suspension from trading or the failure of our Common Stock to be trading or listed on an eligible market for a period of five consecutive trading days would permit the holders to require us to redeem their shares for cash and, in the case of the Series H Preferred Stock, constitutes a triggering event upon which the holders may require us to redeem their shares in cash at a premium or convert their shares into Common Stock at a price as low as the applicable floor price, which would result in substantial dilution to our stockholders. Any such redemption could require us to use a significant portion of our cash and marketable securities. A delisting of our Common Stock could also materially reduce the liquidity of our Common Stock, result in a reduction in the price of our Common Stock, subject our Common Stock to the SEC’s “penny stock” rules, harm our ability to raise capital and cause a loss of confidence by investors, employees and business partners.
We recently terminated our license agreement with LightSolver and shifted our strategic focus to our OPU Initiative, which is at an early stage of development and may not be successful.
On June 26, 2026, we terminated the License Agreement with LightSolver and recorded an impairment charge of $3,177,999 with respect to the related license, and we have determined to fully focus our efforts on our OPU Initiative, which is focused on developing a proprietary silicon photonic computing architecture for artificial intelligence inference. As a result, the risk factors in our annual report on Form 10-K for the fiscal year ended December 31, 2025 relating to our dependence on LightSolver, our laser processing units and the qc-LPU100 no longer describe our current business. The OPU Initiative is at an early stage of development, and we have not yet developed a commercial product. Developing optical computing technologies involves significant technical challenges, including with respect to analog precision, nonlinear computation and memory integration, and will require substantial time, capital and specialized engineering personnel, including our recently appointed Chief Technology Officer. We may not be able to develop prototypes or products that achieve their intended performance, obtain adequate intellectual property protection, or compete successfully with companies that have substantially greater resources. If we are unable to successfully develop and commercialize products under the OPU Initiative, our business, financial condition and results of operations would be materially and adversely affected.
A significant portion of our total assets consists of goodwill, which may become impaired.
As of September 30, 2026, goodwill of $10,498,539 represented approximately 49% of our total assets. We evaluate goodwill for impairment annually and whenever events or changes in circumstances indicate that the fair value of a reporting unit may be less than its carrying amount. As of September 30, 2026, our market capitalization, based on the closing price of our Common Stock of $0.85 per share, was approximately $7.2 million, which was substantially below the carrying amount of our stockholders’ equity of $16,174,679. A sustained decline in our stock price or market capitalization, changes in our strategy or other adverse developments could result in an impairment of all or a portion of our goodwill, which would result in a significant non-cash charge to earnings and a reduction in our stockholders’ equity, which could in turn adversely affect our ability to satisfy Nasdaq’s stockholders’ equity requirement.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
There were no unregistered sales of the Company’s equity securities during the three months ended September 30, 2026, other than those previously reported in a Current Report on Form 8-K.
Item 3. Defaults Upon Senior Securities
There has been no default in the payment of principal, interest, sinking or purchase fund installment, or any other material default, with respect to any indebtedness of the Company.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information.
None
of the Company’s officers or directors
| 54 |
Consent and Warrant Exchange Agreement
On November 15, 2026, the Company entered into a Consent and Warrant Exchange Agreement (the “Consent Agreement”) with PharmaCyte Biotech, Inc. (“PharmaCyte”). Under the Consent Agreement, PharmaCyte agreed to exchange 851,304 Series G Long-Term Warrants (the “Exchange Warrants”) for an aggregate of 4,982,272 shares of the Company’s Common Stock (the “Exchange Shares”). The number of Exchange Shares was determined based on the Black Scholes value of the Exchange Warrants divided by $0.3101 per share, the closing price of the Company’s common stock on the last trading day prior to execution of the Consent Agreement. PharmaCyte paid no additional consideration in the exchange.
The closing occurs upon actual delivery of the Exchange Shares to PharmaCyte, and the Exchange Warrants are cancelled at that time. The exchange is expected to close on or about November 16, 2026. PharmaCyte’s remaining Series G Long-Term Warrants remain outstanding in accordance with their terms.
In addition, PharmaCyte holds more than a majority of the outstanding shares of the Company’s Series H Convertible Preferred Stock (the “Series H Preferred Stock”) and therefore constitutes the “Required Holders” under the Certificate of Designations of the Series H Preferred Stock (the “Series H Certificate of Designations”). In that capacity, PharmaCyte consented under the Consent Agreement to an amendment to the Series H Certificate of Designations that extends the maturity date of the Series H Preferred Stock from March 2, 2027 to September 2, 2027 (the “Series H Amendment”). The Series H Amendment was approved by the special committee of the Board of Directors described below. The Company agreed to file the Series H Amendment with the Secretary of State of the State of Delaware within four business days after the date of the Consent Agreement. Neither the closing of the exchange nor the exchange itself was conditioned on the Series H Amendment, and PharmaCyte paid no additional consideration for the Series H Amendment.
The Consent Agreement also grants PharmaCyte demand registration rights. At any time beginning 90 days after the closing, PharmaCyte may demand that the Company register the resale of the Exchange Shares. Within 30 days after receiving the demand, the Company must file a resale registration statement, use commercially reasonable efforts to have it declared effective, and keep it effective until the Exchange Shares have been sold or may be sold under Rule 144 without restriction. The Company will bear the registration expenses. The Consent Agreement also includes customary indemnification provisions.
As a result of the issuance of the Exchange Shares, and pursuant to the anti-dilution provisions of the applicable certificates of designations and warrants, (i) the conversion price of the Company’s Series G Convertible Preferred Stock and Series H Convertible Preferred Stock was adjusted to $0.3101 per share, and (ii) the exercise price of certain series of the Company’s outstanding warrants was adjusted to $0.3101 per share and the number of shares of Common Stock issuable upon exercise of such warrants was adjusted proportionately. The Company has delivered notice of such adjustments to the affected holders.
PharmaCyte is a related party of the Company. Joshua Silverman, the interim Chief Executive Officer, President and a director of PharmaCyte, serves as the Company’s Chief Executive Officer. PharmaCyte is also a holder of the Company’s Series G Preferred Stock. The Consent Agreement was approved by a special committee of the Board of Directors consisting of independent and disinterested directors. Mr. Silverman did not participate in the special committee’s deliberations or approval.
The Exchange Shares were issued in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”). The exchange is between the Company and an existing security holder, and no commission or other remuneration was paid or given, directly or indirectly, for soliciting the exchange.
The foregoing description of the Consent Agreement is a summary and is qualified in its entirety by the full text of the Consent Agreement, which is filed as Exhibit 10.5 to this Quarterly Report on Form 10-Q and incorporated herein by reference.
Item 6. Exhibits.
Exhibit Number |
Exhibit Description | |
| 10.1# | Employment Agreement, dated March 16, 2026, by and between the Company and Todd Fagan (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2026). | |
| 10.2# | First Amendment to Employment Agreement, dated August 11, 2026, by and between the Company and Todd Fagan (incorporated herein by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2026). | |
| 10.3#+ | Employment Agreement, dated August 1, 2026, by and between the Company and Yossef Ehrlichman (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 18, 2026). | |
| 10.4#+ | First Amendment to Employment Agreement, dated September 14, 2026, by and between the Company and Yossef Ehrlichman (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 18, 2026). | |
10.5+ |
Consent and Warrant Exchange Agreement, dated November 14, 2026, by and between Q/C Technologies, Inc. and PharmaCyte Biotech, Inc. | |
| 31.1+ | Certification of the Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a). | |
| 31.2+ | Certification of the Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a). | |
| 32.1* | Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2* | Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101 | Interactive Data Files of Financial Statements and Notes. | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
+ Filed herewith
* Furnished herewith
# Indicates management contract or compensatory plan or arrangement.
| 55 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Q/C TECHNOLOGIES INC. | ||
| Date: November 16, 2026 | By: | /s/ Joshua Silverman |
| Name: | Joshua Silverman | |
| Title: | Chief Executive Officer | |
| (Principal Executive Officer) | ||
| Date: November 16, 2026 | By: | /s/ Todd Fagan |
| Name: | Todd Fagan | |
| Title: | Chief Financial Officer | |
| (Principal Financial Officer) | ||
| 56 |